{
  "schema_version": "2.0",
  "doc_id": "9e32c903a26b045ee27b2d80e7feb779e01d8733991a579c3a34d3dacc56aaba",
  "extracted_at": "2026-02-01T08:29:51.238013+00:00",
  "extractor": "legacy-migration",
  "entities": [
    {
      "id": "ent_001",
      "type": "Compound",
      "name": "PDE4-inhibitors",
      "attributes": {
        "context": "PDE4-inhibitors"
      },
      "source_chunk_ids": [
        "a99e434cca9478321f4e4df0f62e2c8d"
      ]
    },
    {
      "id": "ent_002",
      "type": "Indication",
      "name": "obstructive airways disease",
      "attributes": {
        "context": "obstructive airways disease"
      },
      "source_chunk_ids": [
        "a99e434cca9478321f4e4df0f62e2c8d"
      ]
    },
    {
      "id": "ent_003",
      "type": "Compound",
      "name": "PDE4-inhibitors",
      "attributes": {
        "context": "PDE4-inhibitors: A novel, targeted therapy"
      },
      "source_chunk_ids": [
        "2b2ce862bf270bbb6f13a157eced763f"
      ]
    },
    {
      "id": "ent_004",
      "type": "Indication",
      "name": "obstructive airways disease",
      "attributes": {
        "context": "targeted therapy for obstructive airways disease"
      },
      "source_chunk_ids": [
        "2b2ce862bf270bbb6f13a157eced763f"
      ]
    },
    {
      "id": "ent_005",
      "type": "Compound",
      "name": "PDE4-inhibitors",
      "attributes": {
        "context": "PDE4-inhibitors: A novel, targeted therapy"
      },
      "source_chunk_ids": [
        "6f70c0e6ceb01d2457b69a48306d4cc8"
      ]
    },
    {
      "id": "ent_006",
      "type": "Indication",
      "name": "obstructive airways disease",
      "attributes": {
        "context": "therapy for obstructive airways disease"
      },
      "source_chunk_ids": [
        "6f70c0e6ceb01d2457b69a48306d4cc8"
      ]
    },
    {
      "id": "ent_007",
      "type": "Indication",
      "name": "Chronic obstructive airways disease (COPD)",
      "attributes": {
        "context": "Chronic obstructive airways disease (COPD) represents a heterogeneous group of disorders"
      },
      "source_chunk_ids": [
        "d05f126c25b11e1889fd080365b5f49b"
      ]
    },
    {
      "id": "ent_008",
      "type": "PharmEffect",
      "name": "chronic inflammation",
      "attributes": {
        "context": "characterized by chronic inflammation of the proximal and the distal airways"
      },
      "source_chunk_ids": [
        "d05f126c25b11e1889fd080365b5f49b"
      ]
    },
    {
      "id": "ent_009",
      "type": "PharmEffect",
      "name": "airway remodeling",
      "attributes": {
        "context": "with features of airway remodeling and destruction"
      },
      "source_chunk_ids": [
        "d05f126c25b11e1889fd080365b5f49b"
      ]
    },
    {
      "id": "ent_010",
      "type": "PharmEffect",
      "name": "destruction",
      "attributes": {
        "context": "with features of airway remodeling and destruction"
      },
      "source_chunk_ids": [
        "d05f126c25b11e1889fd080365b5f49b"
      ]
    },
    {
      "id": "ent_011",
      "type": "PharmEffect",
      "name": "fixed airway obstruction",
      "attributes": {
        "context": "These features present as fixed airway obstruction"
      },
      "source_chunk_ids": [
        "d05f126c25b11e1889fd080365b5f49b"
      ]
    },
    {
      "id": "ent_012",
      "type": "PharmEffect",
      "name": "hyperinflation",
      "attributes": {
        "context": "hyperinflation, dyspnea, mucus hypersecretion and chronic cough"
      },
      "source_chunk_ids": [
        "d05f126c25b11e1889fd080365b5f49b"
      ]
    },
    {
      "id": "ent_013",
      "type": "Indication",
      "name": "dyspnea",
      "attributes": {
        "context": "hyperinflation, dyspnea, mucus hypersecretion and chronic cough"
      },
      "source_chunk_ids": [
        "d05f126c25b11e1889fd080365b5f49b"
      ]
    },
    {
      "id": "ent_014",
      "type": "PharmEffect",
      "name": "mucus hypersecretion",
      "attributes": {
        "context": "hyperinflation, dyspnea, mucus hypersecretion and chronic cough"
      },
      "source_chunk_ids": [
        "d05f126c25b11e1889fd080365b5f49b"
      ]
    },
    {
      "id": "ent_015",
      "type": "Indication",
      "name": "chronic cough",
      "attributes": {
        "context": "hyperinflation, dyspnea, mucus hypersecretion and chronic cough"
      },
      "source_chunk_ids": [
        "d05f126c25b11e1889fd080365b5f49b"
      ]
    },
    {
      "id": "ent_016",
      "type": "PharmEffect",
      "name": "structural changes",
      "attributes": {
        "context": "including structural changes and destruction of alveolar tissue"
      },
      "source_chunk_ids": [
        "d05f126c25b11e1889fd080365b5f49b"
      ]
    },
    {
      "id": "ent_017",
      "type": "PharmEffect",
      "name": "destruction of alveolar tissue",
      "attributes": {
        "context": "including structural changes and destruction of alveolar tissue"
      },
      "source_chunk_ids": [
        "d05f126c25b11e1889fd080365b5f49b"
      ]
    },
    {
      "id": "ent_018",
      "type": "PharmEffect",
      "name": "Phosphodiesterase inhibition",
      "attributes": {
        "context": "Phosphodiesterase inhibition is an old concept"
      },
      "source_chunk_ids": [
        "577d177f1cd27b22ce2d1d8fc371d264"
      ]
    },
    {
      "id": "ent_019",
      "type": "Indication",
      "name": "COPD",
      "attributes": {
        "context": "treatment of COPD"
      },
      "source_chunk_ids": [
        "577d177f1cd27b22ce2d1d8fc371d264"
      ]
    },
    {
      "id": "ent_020",
      "type": "Compound",
      "name": "aminophylline",
      "attributes": {
        "context": "PDE)-inhibitors, aminophylline and theophylline"
      },
      "source_chunk_ids": [
        "577d177f1cd27b22ce2d1d8fc371d264"
      ]
    },
    {
      "id": "ent_021",
      "type": "Compound",
      "name": "theophylline",
      "attributes": {
        "context": "PDE)-inhibitors, aminophylline and theophylline"
      },
      "source_chunk_ids": [
        "577d177f1cd27b22ce2d1d8fc371d264"
      ]
    },
    {
      "id": "ent_022",
      "type": "PharmEffect",
      "name": "drug-interactions",
      "attributes": {
        "context": "limited by many drug-interactions"
      },
      "source_chunk_ids": [
        "577d177f1cd27b22ce2d1d8fc371d264"
      ]
    },
    {
      "id": "ent_023",
      "type": "Concentration",
      "name": "narrow dose-range",
      "attributes": {
        "context": "a narrow dose-range"
      },
      "source_chunk_ids": [
        "577d177f1cd27b22ce2d1d8fc371d264"
      ]
    },
    {
      "id": "ent_024",
      "type": "PharmEffect",
      "name": "cardiovascular side effects",
      "attributes": {
        "context": "mostly cardiovascular and gastrointestinal side effects"
      },
      "source_chunk_ids": [
        "577d177f1cd27b22ce2d1d8fc371d264"
      ]
    },
    {
      "id": "ent_025",
      "type": "PharmEffect",
      "name": "gastrointestinal side effects",
      "attributes": {
        "context": "mostly cardiovascular and gastrointestinal side effects"
      },
      "source_chunk_ids": [
        "577d177f1cd27b22ce2d1d8fc371d264"
      ]
    },
    {
      "id": "ent_026",
      "type": "Compound",
      "name": "theophylline",
      "attributes": {
        "context": "Whilst theophylline may non-selectively target PDE"
      },
      "source_chunk_ids": [
        "577d177f1cd27b22ce2d1d8fc371d264"
      ]
    },
    {
      "id": "ent_027",
      "type": "Concentration",
      "name": "high concentrations",
      "attributes": {
        "context": "albeit at high concentrations"
      },
      "source_chunk_ids": [
        "577d177f1cd27b22ce2d1d8fc371d264"
      ]
    },
    {
      "id": "ent_028",
      "type": "PharmEffect",
      "name": "inhibition of phosphoinositide 3 kinase",
      "attributes": {
        "context": "inhibition of phosphoinositide 3 kinase as a target"
      },
      "source_chunk_ids": [
        "577d177f1cd27b22ce2d1d8fc371d264"
      ]
    },
    {
      "id": "ent_029",
      "type": "PharmEffect",
      "name": "anti-inflammatory action",
      "attributes": {
        "context": "anti-inflammatory action of this drug"
      },
      "source_chunk_ids": [
        "577d177f1cd27b22ce2d1d8fc371d264"
      ]
    },
    {
      "id": "ent_030",
      "type": "PharmEffect",
      "name": "targeted therapy",
      "attributes": {
        "context": "enabling targeted therapy"
      },
      "source_chunk_ids": [
        "577d177f1cd27b22ce2d1d8fc371d264"
      ]
    },
    {
      "id": "ent_031",
      "type": "PharmEffect",
      "name": "systemic side effects",
      "attributes": {
        "context": "potentially fewer (systemic) side effects"
      },
      "source_chunk_ids": [
        "577d177f1cd27b22ce2d1d8fc371d264"
      ]
    },
    {
      "id": "ent_032",
      "type": "PharmEffect",
      "name": "non-selective PDE-inhibition",
      "attributes": {
        "context": "in contrast to non-selective PDE-inhibition"
      },
      "source_chunk_ids": [
        "577d177f1cd27b22ce2d1d8fc371d264"
      ]
    },
    {
      "id": "ent_033",
      "type": "PharmEffect",
      "name": "selectively targeting the PDE4-isoenzyme",
      "attributes": {
        "context": "selectively targeting the PDE4-isoenzyme"
      },
      "source_chunk_ids": [
        "577d177f1cd27b22ce2d1d8fc371d264"
      ]
    },
    {
      "id": "ent_034",
      "type": "Indication",
      "name": "COPD",
      "attributes": {
        "context": "implicated in COPD"
      },
      "source_chunk_ids": [
        "577d177f1cd27b22ce2d1d8fc371d264"
      ]
    },
    {
      "id": "ent_035",
      "type": "PharmEffect",
      "name": "disease modifying therapy",
      "attributes": {
        "context": "promising target for disease modifying therapy"
      },
      "source_chunk_ids": [
        "577d177f1cd27b22ce2d1d8fc371d264"
      ]
    },
    {
      "id": "ent_036",
      "type": "PharmEffect",
      "name": "chronic airway inflammation",
      "attributes": {
        "context": "strong relationship between chronic airway inflammation"
      },
      "source_chunk_ids": [
        "577d177f1cd27b22ce2d1d8fc371d264"
      ]
    },
    {
      "id": "ent_037",
      "type": "PharmEffect",
      "name": "mucus hypersecretion",
      "attributes": {
        "context": "mucus hypersecretion with increased decline in lung function"
      },
      "source_chunk_ids": [
        "577d177f1cd27b22ce2d1d8fc371d264"
      ]
    },
    {
      "id": "ent_038",
      "type": "PharmEffect",
      "name": "increased decline in lung function",
      "attributes": {
        "context": "increased decline in lung function"
      },
      "source_chunk_ids": [
        "577d177f1cd27b22ce2d1d8fc371d264"
      ]
    },
    {
      "id": "ent_039",
      "type": "Indication",
      "name": "COPD",
      "attributes": {
        "context": "studies in COPD"
      },
      "source_chunk_ids": [
        "577d177f1cd27b22ce2d1d8fc371d264"
      ]
    },
    {
      "id": "ent_040",
      "type": "Compound",
      "name": "cilomilast",
      "attributes": {
        "context": "oral PDE4-inhibitors, cilomilast (Glaxo Smith Kline)"
      },
      "source_chunk_ids": [
        "577d177f1cd27b22ce2d1d8fc371d264"
      ]
    },
    {
      "id": "ent_041",
      "type": "Compound",
      "name": "roflumilast",
      "attributes": {
        "context": "cilomilast (Glaxo Smith Kline) and roflumilast (Nycomed)"
      },
      "source_chunk_ids": [
        "577d177f1cd27b22ce2d1d8fc371d264"
      ]
    },
    {
      "id": "ent_042",
      "type": "Compound",
      "name": "PDE4-inhibitors",
      "attributes": {
        "context": "various PDE4-inhibitors appeared to be poor functional antagonists"
      },
      "source_chunk_ids": [
        "b8f1dac29022a4872ad9bc6d1d9f23e1"
      ]
    },
    {
      "id": "ent_043",
      "type": "PharmEffect",
      "name": "relaxation of airway smooth muscle",
      "attributes": {
        "context": "produced modest relaxation of airway smooth muscle"
      },
      "source_chunk_ids": [
        "b8f1dac29022a4872ad9bc6d1d9f23e1"
      ]
    },
    {
      "id": "ent_044",
      "type": "Compound",
      "name": "cilomilast",
      "attributes": {
        "context": "study with cilomilast confirmed the previously observed improvements"
      },
      "source_chunk_ids": [
        "b8f1dac29022a4872ad9bc6d1d9f23e1"
      ]
    },
    {
      "id": "ent_045",
      "type": "PharmEffect",
      "name": "improvements in lung function",
      "attributes": {
        "context": "observed improvements in lung function"
      },
      "source_chunk_ids": [
        "b8f1dac29022a4872ad9bc6d1d9f23e1"
      ]
    },
    {
      "id": "ent_046",
      "type": "PharmEffect",
      "name": "reduction in COPD exacerbations",
      "attributes": {
        "context": "showed a significant reduction in COPD exacerbations"
      },
      "source_chunk_ids": [
        "b8f1dac29022a4872ad9bc6d1d9f23e1"
      ]
    },
    {
      "id": "ent_047",
      "type": "Indication",
      "name": "COPD exacerbations",
      "attributes": {
        "context": "reduction in COPD exacerbations"
      },
      "source_chunk_ids": [
        "b8f1dac29022a4872ad9bc6d1d9f23e1"
      ]
    },
    {
      "id": "ent_048",
      "type": "PharmEffect",
      "name": "improvements in quality of life scores",
      "attributes": {
        "context": "improvements in quality of life scores"
      },
      "source_chunk_ids": [
        "b8f1dac29022a4872ad9bc6d1d9f23e1"
      ]
    },
    {
      "id": "ent_049",
      "type": "PharmEffect",
      "name": "anti-inflammatory activity",
      "attributes": {
        "context": "attributed to an anti-inflammatory activity"
      },
      "source_chunk_ids": [
        "b8f1dac29022a4872ad9bc6d1d9f23e1"
      ]
    },
    {
      "id": "ent_050",
      "type": "Compound",
      "name": "cilomilast",
      "attributes": {
        "context": "cilomilast has been shown to reduce the number of several pro-inflammatory cells"
      },
      "source_chunk_ids": [
        "b8f1dac29022a4872ad9bc6d1d9f23e1"
      ]
    },
    {
      "id": "ent_051",
      "type": "PharmEffect",
      "name": "reduce the number of several pro-inflammatory cells",
      "attributes": {
        "context": "cilomilast has been shown to reduce the number of several pro-inflammatory cells"
      },
      "source_chunk_ids": [
        "b8f1dac29022a4872ad9bc6d1d9f23e1"
      ]
    },
    {
      "id": "ent_052",
      "type": "Indication",
      "name": "COPD",
      "attributes": {
        "context": "implicated in the pathogenesis of COPD"
      },
      "source_chunk_ids": [
        "b8f1dac29022a4872ad9bc6d1d9f23e1"
      ]
    },
    {
      "id": "ent_053",
      "type": "Concentration",
      "name": "approximately 40-50%",
      "attributes": {
        "context": "from subjects with COPD by approximately 40-50%"
      },
      "source_chunk_ids": [
        "b8f1dac29022a4872ad9bc6d1d9f23e1"
      ]
    },
    {
      "id": "ent_054",
      "type": "PharmEffect",
      "name": "improvements in lung function",
      "attributes": {
        "context": "improvements in lung function were not maintained"
      },
      "source_chunk_ids": [
        "b8f1dac29022a4872ad9bc6d1d9f23e1"
      ]
    },
    {
      "id": "ent_055",
      "type": "PharmEffect",
      "name": "improvements in lung function",
      "attributes": {
        "context": "explanations for the improvements in lung function"
      },
      "source_chunk_ids": [
        "b8f1dac29022a4872ad9bc6d1d9f23e1"
      ]
    },
    {
      "id": "ent_056",
      "type": "PharmEffect",
      "name": "exacerbation rates",
      "attributes": {
        "context": "exacerbation rates and quality of life"
      },
      "source_chunk_ids": [
        "b8f1dac29022a4872ad9bc6d1d9f23e1"
      ]
    },
    {
      "id": "ent_057",
      "type": "PharmEffect",
      "name": "quality of life",
      "attributes": {
        "context": "quality of life additional to the indirect bronchodilator effect"
      },
      "source_chunk_ids": [
        "b8f1dac29022a4872ad9bc6d1d9f23e1"
      ]
    },
    {
      "id": "ent_058",
      "type": "PharmEffect",
      "name": "bronchodilator effect",
      "attributes": {
        "context": "indirect bronchodilator effect of cilomilast"
      },
      "source_chunk_ids": [
        "b8f1dac29022a4872ad9bc6d1d9f23e1"
      ]
    },
    {
      "id": "ent_059",
      "type": "Compound",
      "name": "cilomilast",
      "attributes": {
        "context": "bronchodilator effect of cilomilast seen in a majority"
      },
      "source_chunk_ids": [
        "b8f1dac29022a4872ad9bc6d1d9f23e1"
      ]
    },
    {
      "id": "ent_060",
      "type": "PharmEffect",
      "name": "modulation of sensory nerve function",
      "attributes": {
        "context": "attributed to a modulation of sensory nerve function"
      },
      "source_chunk_ids": [
        "b8f1dac29022a4872ad9bc6d1d9f23e1"
      ]
    },
    {
      "id": "ent_061",
      "type": "PharmEffect",
      "name": "reduction in contraction of airway smooth muscle",
      "attributes": {
        "context": "a reduction in contraction of airway smooth muscle"
      },
      "source_chunk_ids": [
        "b8f1dac29022a4872ad9bc6d1d9f23e1"
      ]
    },
    {
      "id": "ent_062",
      "type": "PharmEffect",
      "name": "improvements in airflow",
      "attributes": {
        "context": "leading to improvements in airflow and symptoms"
      },
      "source_chunk_ids": [
        "b8f1dac29022a4872ad9bc6d1d9f23e1"
      ]
    },
    {
      "id": "ent_063",
      "type": "PharmEffect",
      "name": "improvements in symptoms",
      "attributes": {
        "context": "improvements in airflow and symptoms"
      },
      "source_chunk_ids": [
        "b8f1dac29022a4872ad9bc6d1d9f23e1"
      ]
    },
    {
      "id": "ent_064",
      "type": "Compound",
      "name": "cyclic AMP",
      "attributes": {
        "context": "elevating the level of cyclic AMP in airway epithelial cells"
      },
      "source_chunk_ids": [
        "b8f1dac29022a4872ad9bc6d1d9f23e1"
      ]
    },
    {
      "id": "ent_065",
      "type": "PharmEffect",
      "name": "rehydration of the epithelial periciliary layer",
      "attributes": {
        "context": "promote rehydration of the epithelial periciliary layer"
      },
      "source_chunk_ids": [
        "b8f1dac29022a4872ad9bc6d1d9f23e1"
      ]
    },
    {
      "id": "ent_066",
      "type": "PharmEffect",
      "name": "facilitating mucociliary clearance of mucus and bacteria",
      "attributes": {
        "context": "facilitating mucociliary clearance of mucus and bacteria"
      },
      "source_chunk_ids": [
        "b8f1dac29022a4872ad9bc6d1d9f23e1"
      ]
    },
    {
      "id": "ent_067",
      "type": "Compound",
      "name": "PDE4 inhibitors",
      "attributes": {
        "context": "PDE4 inhibitors can reduce mucus production"
      },
      "source_chunk_ids": [
        "b8f1dac29022a4872ad9bc6d1d9f23e1"
      ]
    },
    {
      "id": "ent_068",
      "type": "PharmEffect",
      "name": "reduce mucus production",
      "attributes": {
        "context": "PDE4 inhibitors can reduce mucus production"
      },
      "source_chunk_ids": [
        "b8f1dac29022a4872ad9bc6d1d9f23e1"
      ]
    },
    {
      "id": "ent_069",
      "type": "PharmEffect",
      "name": "increase ciliary beat frequency",
      "attributes": {
        "context": "increase ciliary beat frequency of airway epithelial cells"
      },
      "source_chunk_ids": [
        "b8f1dac29022a4872ad9bc6d1d9f23e1"
      ]
    },
    {
      "id": "ent_070",
      "type": "Compound",
      "name": "cilomilast",
      "attributes": {
        "context": "studies with cilomilast"
      },
      "source_chunk_ids": [
        "da025e1e40f7f7ab07600fa502c279bc"
      ]
    },
    {
      "id": "ent_071",
      "type": "PharmEffect",
      "name": "efficacy",
      "attributes": {
        "context": "clinical efficacy"
      },
      "source_chunk_ids": [
        "da025e1e40f7f7ab07600fa502c279bc"
      ]
    },
    {
      "id": "ent_072",
      "type": "PharmEffect",
      "name": "safety",
      "attributes": {
        "context": "safety data"
      },
      "source_chunk_ids": [
        "da025e1e40f7f7ab07600fa502c279bc"
      ]
    },
    {
      "id": "ent_073",
      "type": "PharmEffect",
      "name": "efficacy",
      "attributes": {
        "context": "efficacy endpoints"
      },
      "source_chunk_ids": [
        "da025e1e40f7f7ab07600fa502c279bc"
      ]
    },
    {
      "id": "ent_074",
      "type": "PharmEffect",
      "name": "improvement in lung function",
      "attributes": {
        "context": "significant improvement in lung function"
      },
      "source_chunk_ids": [
        "da025e1e40f7f7ab07600fa502c279bc"
      ]
    },
    {
      "id": "ent_075",
      "type": "Concentration",
      "name": "24 weeks",
      "attributes": {
        "context": "following 24 weeks of treatment"
      },
      "source_chunk_ids": [
        "da025e1e40f7f7ab07600fa502c279bc"
      ]
    },
    {
      "id": "ent_076",
      "type": "Compound",
      "name": "cilomilast",
      "attributes": {
        "context": "treatment with cilomilast"
      },
      "source_chunk_ids": [
        "da025e1e40f7f7ab07600fa502c279bc"
      ]
    },
    {
      "id": "ent_077",
      "type": "PharmEffect",
      "name": "gastrointestinal side effects",
      "attributes": {
        "context": "gastrointestinal side effects"
      },
      "source_chunk_ids": [
        "da025e1e40f7f7ab07600fa502c279bc"
      ]
    },
    {
      "id": "ent_078",
      "type": "Concentration",
      "name": "2 weeks",
      "attributes": {
        "context": "within the first 2 weeks of treatment"
      },
      "source_chunk_ids": [
        "da025e1e40f7f7ab07600fa502c279bc"
      ]
    },
    {
      "id": "ent_079",
      "type": "Compound",
      "name": "cilomilast",
      "attributes": {
        "context": "development of cilomilast was terminated"
      },
      "source_chunk_ids": [
        "ca56fecc0c58a63afb012aa76d83baf2"
      ]
    },
    {
      "id": "ent_080",
      "type": "Compound",
      "name": "cilomilast",
      "attributes": {
        "context": "failure of cilomilast"
      },
      "source_chunk_ids": [
        "12e35efaee014f47451619f7b5f942e1"
      ]
    },
    {
      "id": "ent_081",
      "type": "Compound",
      "name": "PDE4",
      "attributes": {
        "context": "targeting PDE4"
      },
      "source_chunk_ids": [
        "12e35efaee014f47451619f7b5f942e1"
      ]
    },
    {
      "id": "ent_082",
      "type": "Indication",
      "name": "COPD",
      "attributes": {
        "context": "treatment of COPD"
      },
      "source_chunk_ids": [
        "12e35efaee014f47451619f7b5f942e1"
      ]
    },
    {
      "id": "ent_083",
      "type": "PharmEffect",
      "name": "PDE4-inhibition",
      "attributes": {
        "context": "sustained PDE4-inhibition"
      },
      "source_chunk_ids": [
        "12e35efaee014f47451619f7b5f942e1"
      ]
    },
    {
      "id": "ent_084",
      "type": "Compound",
      "name": "roflumilast",
      "attributes": {
        "context": "PDE4-inhibitor roflumilast"
      },
      "source_chunk_ids": [
        "12e35efaee014f47451619f7b5f942e1"
      ]
    },
    {
      "id": "ent_085",
      "type": "PharmEffect",
      "name": "PDE4-inhibitor",
      "attributes": {
        "context": "highly potent, once daily PDE4-inhibitor"
      },
      "source_chunk_ids": [
        "12e35efaee014f47451619f7b5f942e1"
      ]
    },
    {
      "id": "ent_086",
      "type": "Concentration",
      "name": "once daily",
      "attributes": {
        "context": "once daily PDE4-inhibitor"
      },
      "source_chunk_ids": [
        "12e35efaee014f47451619f7b5f942e1"
      ]
    },
    {
      "id": "ent_087",
      "type": "Compound",
      "name": "Roflumilast",
      "attributes": {
        "context": "Roflumilast: pharmacokinetics"
      },
      "source_chunk_ids": [
        "678229b8f4cae32364deccabdb6d285e"
      ]
    },
    {
      "id": "ent_088",
      "type": "Compound",
      "name": "roflumilast",
      "attributes": {
        "context": "roflumilast is rapidly absorbed"
      },
      "source_chunk_ids": [
        "bd1d5728b17cf842c58e616ac92b9f31"
      ]
    },
    {
      "id": "ent_089",
      "type": "Concentration",
      "name": "250-1000 mcg",
      "attributes": {
        "context": "Over a dose-range of 250-1000 mcg"
      },
      "source_chunk_ids": [
        "bd1d5728b17cf842c58e616ac92b9f31"
      ]
    },
    {
      "id": "ent_090",
      "type": "Compound",
      "name": "roflumilast",
      "attributes": {
        "context": "roflumilast shows linearly dose-proportional pharmacokinetics"
      },
      "source_chunk_ids": [
        "bd1d5728b17cf842c58e616ac92b9f31"
      ]
    },
    {
      "id": "ent_091",
      "type": "Compound",
      "name": "Roflumilast",
      "attributes": {
        "context": "Roflumilast is rapidly metabolized by CYP3A4 and CYP1A2 enzymes"
      },
      "source_chunk_ids": [
        "bd1d5728b17cf842c58e616ac92b9f31"
      ]
    },
    {
      "id": "ent_092",
      "type": "Compound",
      "name": "CYP3A4",
      "attributes": {
        "context": "metabolized by CYP3A4 and CYP1A2 enzymes"
      },
      "source_chunk_ids": [
        "bd1d5728b17cf842c58e616ac92b9f31"
      ]
    },
    {
      "id": "ent_093",
      "type": "Compound",
      "name": "CYP1A2",
      "attributes": {
        "context": "metabolized by CYP3A4 and CYP1A2 enzymes"
      },
      "source_chunk_ids": [
        "bd1d5728b17cf842c58e616ac92b9f31"
      ]
    },
    {
      "id": "ent_094",
      "type": "Compound",
      "name": "N-oxide",
      "attributes": {
        "context": "N-oxide, being the major metabolite of roflumilast"
      },
      "source_chunk_ids": [
        "bd1d5728b17cf842c58e616ac92b9f31"
      ]
    },
    {
      "id": "ent_095",
      "type": "Compound",
      "name": "roflumilast",
      "attributes": {
        "context": "major metabolite of roflumilast"
      },
      "source_chunk_ids": [
        "bd1d5728b17cf842c58e616ac92b9f31"
      ]
    },
    {
      "id": "ent_096",
      "type": "Compound",
      "name": "PDE4 isoenzymes",
      "attributes": {
        "context": "possesses selectivity for the PDE4 isoenzymes"
      },
      "source_chunk_ids": [
        "bd1d5728b17cf842c58e616ac92b9f31"
      ]
    },
    {
      "id": "ent_097",
      "type": "Compound",
      "name": "PDE4 subtypes",
      "attributes": {
        "context": "not for PDE4 subtypes"
      },
      "source_chunk_ids": [
        "bd1d5728b17cf842c58e616ac92b9f31"
      ]
    },
    {
      "id": "ent_098",
      "type": "Compound",
      "name": "roflumilast",
      "attributes": {
        "context": "Both roflumilast and N-oxide are mainly excreted"
      },
      "source_chunk_ids": [
        "bd1d5728b17cf842c58e616ac92b9f31"
      ]
    },
    {
      "id": "ent_099",
      "type": "Compound",
      "name": "N-oxide",
      "attributes": {
        "context": "Both roflumilast and N-oxide are mainly excreted"
      },
      "source_chunk_ids": [
        "bd1d5728b17cf842c58e616ac92b9f31"
      ]
    },
    {
      "id": "ent_100",
      "type": "Compound",
      "name": "roflumilast",
      "attributes": {
        "context": "between roflumilast and other (COPD-related) pharmacological treatments"
      },
      "source_chunk_ids": [
        "bd1d5728b17cf842c58e616ac92b9f31"
      ]
    },
    {
      "id": "ent_101",
      "type": "Indication",
      "name": "COPD",
      "attributes": {
        "context": "(COPD-related) pharmacological treatments"
      },
      "source_chunk_ids": [
        "bd1d5728b17cf842c58e616ac92b9f31"
      ]
    },
    {
      "id": "ent_102",
      "type": "Indication",
      "name": "exacerbations",
      "attributes": {
        "context": "exacerbations (p=0.0114)"
      },
      "source_chunk_ids": [
        "4b04451fef8aaea9305e782c5693abb7"
      ]
    },
    {
      "id": "ent_103",
      "type": "Indication",
      "name": "COPD",
      "attributes": {
        "context": "severe COPD (GOLD stages II to IV)"
      },
      "source_chunk_ids": [
        "4b04451fef8aaea9305e782c5693abb7"
      ]
    },
    {
      "id": "ent_104",
      "type": "Compound",
      "name": "roflumilast",
      "attributes": {
        "context": "received roflumilast for one year"
      },
      "source_chunk_ids": [
        "4b04451fef8aaea9305e782c5693abb7"
      ]
    },
    {
      "id": "ent_105",
      "type": "Concentration",
      "name": "one year",
      "attributes": {
        "context": "roflumilast for one year"
      },
      "source_chunk_ids": [
        "4b04451fef8aaea9305e782c5693abb7"
      ]
    },
    {
      "id": "ent_106",
      "type": "PharmEffect",
      "name": "improvement in baseline FEV1",
      "attributes": {
        "context": "significant improvement in baseline FEV1"
      },
      "source_chunk_ids": [
        "4b04451fef8aaea9305e782c5693abb7"
      ]
    },
    {
      "id": "ent_107",
      "type": "PharmEffect",
      "name": "reduction in exacerbation rates",
      "attributes": {
        "context": "modest reduction in exacerbation rates"
      },
      "source_chunk_ids": [
        "4b04451fef8aaea9305e782c5693abb7"
      ]
    },
    {
      "id": "ent_108",
      "type": "Compound",
      "name": "roflumilast",
      "attributes": {
        "context": "randomized controlled trials (RCT) with roflumilast"
      },
      "source_chunk_ids": [
        "c674c321267d06ecbf909fb4707589a9"
      ]
    },
    {
      "id": "ent_109",
      "type": "Indication",
      "name": "COPD",
      "attributes": {
        "context": "moderate to severe COPD"
      },
      "source_chunk_ids": [
        "c674c321267d06ecbf909fb4707589a9"
      ]
    },
    {
      "id": "ent_110",
      "type": "PharmEffect",
      "name": "lung function",
      "attributes": {
        "context": "effect on lung function"
      },
      "source_chunk_ids": [
        "c674c321267d06ecbf909fb4707589a9"
      ]
    },
    {
      "id": "ent_111",
      "type": "Compound",
      "name": "roflumilast",
      "attributes": {
        "context": "efficacy of roflumilast"
      },
      "source_chunk_ids": [
        "c674c321267d06ecbf909fb4707589a9"
      ]
    },
    {
      "id": "ent_112",
      "type": "Indication",
      "name": "COPD-exacerbations",
      "attributes": {
        "context": "prevention and treatment of COPD-exacerbations"
      },
      "source_chunk_ids": [
        "c674c321267d06ecbf909fb4707589a9"
      ]
    },
    {
      "id": "ent_113",
      "type": "PharmEffect",
      "name": "prevention",
      "attributes": {
        "context": "prevention and treatment of COPD-exacerbations"
      },
      "source_chunk_ids": [
        "c674c321267d06ecbf909fb4707589a9"
      ]
    },
    {
      "id": "ent_114",
      "type": "PharmEffect",
      "name": "treatment",
      "attributes": {
        "context": "prevention and treatment of COPD-exacerbations"
      },
      "source_chunk_ids": [
        "c674c321267d06ecbf909fb4707589a9"
      ]
    },
    {
      "id": "ent_115",
      "type": "PharmEffect",
      "name": "safety/tolerability",
      "attributes": {
        "context": "safety/tolerability"
      },
      "source_chunk_ids": [
        "c674c321267d06ecbf909fb4707589a9"
      ]
    },
    {
      "id": "ent_116",
      "type": "Indication",
      "name": "COPD",
      "attributes": {
        "context": "studies in COPD"
      },
      "source_chunk_ids": [
        "c674c321267d06ecbf909fb4707589a9"
      ]
    },
    {
      "id": "ent_117",
      "type": "PharmEffect",
      "name": "treatment",
      "attributes": {
        "context": "effects of treatment"
      },
      "source_chunk_ids": [
        "c674c321267d06ecbf909fb4707589a9"
      ]
    },
    {
      "id": "ent_118",
      "type": "Compound",
      "name": "roflumilast",
      "attributes": {
        "context": "treatment with roflumilast"
      },
      "source_chunk_ids": [
        "c674c321267d06ecbf909fb4707589a9"
      ]
    },
    {
      "id": "ent_119",
      "type": "Compound",
      "name": "placebo",
      "attributes": {
        "context": "roflumilast versus placebo"
      },
      "source_chunk_ids": [
        "c674c321267d06ecbf909fb4707589a9"
      ]
    },
    {
      "id": "ent_120",
      "type": "Compound",
      "name": "salmeterol",
      "attributes": {
        "context": "addition to salmeterol"
      },
      "source_chunk_ids": [
        "c674c321267d06ecbf909fb4707589a9"
      ]
    },
    {
      "id": "ent_121",
      "type": "Compound",
      "name": "tiotropium",
      "attributes": {
        "context": "or tiotropium"
      },
      "source_chunk_ids": [
        "c674c321267d06ecbf909fb4707589a9"
      ]
    },
    {
      "id": "ent_122",
      "type": "Indication",
      "name": "moderate to severe COPD",
      "attributes": {
        "context": "patients with moderate to severe COPD"
      },
      "source_chunk_ids": [
        "c674c321267d06ecbf909fb4707589a9"
      ]
    },
    {
      "id": "ent_123",
      "type": "Compound",
      "name": "roflumilast",
      "attributes": {
        "context": "either roflumilast (n=466)"
      },
      "source_chunk_ids": [
        "c674c321267d06ecbf909fb4707589a9"
      ]
    },
    {
      "id": "ent_124",
      "type": "Compound",
      "name": "placebo",
      "attributes": {
        "context": "or placebo (n=467)"
      },
      "source_chunk_ids": [
        "c674c321267d06ecbf909fb4707589a9"
      ]
    },
    {
      "id": "ent_125",
      "type": "Compound",
      "name": "salmeterol",
      "attributes": {
        "context": "combination with salmeterol"
      },
      "source_chunk_ids": [
        "c674c321267d06ecbf909fb4707589a9"
      ]
    },
    {
      "id": "ent_126",
      "type": "Compound",
      "name": "roflumilast",
      "attributes": {
        "context": "either roflumilast (n=371)"
      },
      "source_chunk_ids": [
        "c674c321267d06ecbf909fb4707589a9"
      ]
    },
    {
      "id": "ent_127",
      "type": "Compound",
      "name": "placebo",
      "attributes": {
        "context": "or placebo (n=372)"
      },
      "source_chunk_ids": [
        "c674c321267d06ecbf909fb4707589a9"
      ]
    },
    {
      "id": "ent_128",
      "type": "Compound",
      "name": "tiotropium",
      "attributes": {
        "context": "combination with tiotropium"
      },
      "source_chunk_ids": [
        "c674c321267d06ecbf909fb4707589a9"
      ]
    },
    {
      "id": "ent_129",
      "type": "Compound",
      "name": "inhaled corticosteroids",
      "attributes": {
        "context": "using inhaled corticosteroids"
      },
      "source_chunk_ids": [
        "c674c321267d06ecbf909fb4707589a9"
      ]
    },
    {
      "id": "ent_130",
      "type": "Indication",
      "name": "chronic cough",
      "attributes": {
        "context": "symptomatic patients with chronic cough"
      },
      "source_chunk_ids": [
        "c674c321267d06ecbf909fb4707589a9"
      ]
    },
    {
      "id": "ent_131",
      "type": "Indication",
      "name": "sputum production",
      "attributes": {
        "context": "and sputum production"
      },
      "source_chunk_ids": [
        "c674c321267d06ecbf909fb4707589a9"
      ]
    },
    {
      "id": "ent_132",
      "type": "Compound",
      "name": "short-acting bronchodilators",
      "attributes": {
        "context": "use of short-acting bronchodilators"
      },
      "source_chunk_ids": [
        "c674c321267d06ecbf909fb4707589a9"
      ]
    },
    {
      "id": "ent_133",
      "type": "Compound",
      "name": "roflumilast",
      "attributes": {
        "context": "roflumilast was associated with consistent and sustained improvements"
      },
      "source_chunk_ids": [
        "c674c321267d06ecbf909fb4707589a9"
      ]
    },
    {
      "id": "ent_134",
      "type": "PharmEffect",
      "name": "improvements",
      "attributes": {
        "context": "sustained improvements in both the pre- and post-bronchodilator FEV1"
      },
      "source_chunk_ids": [
        "c674c321267d06ecbf909fb4707589a9"
      ]
    },
    {
      "id": "ent_135",
      "type": "PharmEffect",
      "name": "FEV1",
      "attributes": {
        "context": "pre- and post-bronchodilator FEV1"
      },
      "source_chunk_ids": [
        "c674c321267d06ecbf909fb4707589a9"
      ]
    },
    {
      "id": "ent_136",
      "type": "Compound",
      "name": "salmeterol",
      "attributes": {
        "context": "In the salmeterol-combination"
      },
      "source_chunk_ids": [
        "c674c321267d06ecbf909fb4707589a9"
      ]
    },
    {
      "id": "ent_137",
      "type": "PharmEffect",
      "name": "FEV1",
      "attributes": {
        "context": "increase in pre-bronchodilator FEV1"
      },
      "source_chunk_ids": [
        "c674c321267d06ecbf909fb4707589a9"
      ]
    },
    {
      "id": "ent_138",
      "type": "Compound",
      "name": "placebo",
      "attributes": {
        "context": "FEV1 versus placebo"
      },
      "source_chunk_ids": [
        "c674c321267d06ecbf909fb4707589a9"
      ]
    },
    {
      "id": "ent_139",
      "type": "Compound",
      "name": "tiotropium",
      "attributes": {
        "context": "in the tiotropium-combination"
      },
      "source_chunk_ids": [
        "c674c321267d06ecbf909fb4707589a9"
      ]
    },
    {
      "id": "ent_140",
      "type": "Compound",
      "name": "roflumilast",
      "attributes": {
        "context": "patients on roflumilast tended to have fewer exacerbations"
      },
      "source_chunk_ids": [
        "c674c321267d06ecbf909fb4707589a9"
      ]
    },
    {
      "id": "ent_141",
      "type": "PharmEffect",
      "name": "fewer exacerbations",
      "attributes": {
        "context": "tended to have fewer exacerbations"
      },
      "source_chunk_ids": [
        "c674c321267d06ecbf909fb4707589a9"
      ]
    },
    {
      "id": "ent_142",
      "type": "Compound",
      "name": "roflumilast",
      "attributes": {
        "context": "larger in the roflumilast-arm"
      },
      "source_chunk_ids": [
        "c674c321267d06ecbf909fb4707589a9"
      ]
    },
    {
      "id": "ent_143",
      "type": "Compound",
      "name": "salmeterol",
      "attributes": {
        "context": "in the salmeterol-roflumilast-arm"
      },
      "source_chunk_ids": [
        "c674c321267d06ecbf909fb4707589a9"
      ]
    },
    {
      "id": "ent_144",
      "type": "Compound",
      "name": "roflumilast",
      "attributes": {
        "context": "roflumilast-related side effects"
      },
      "source_chunk_ids": [
        "c674c321267d06ecbf909fb4707589a9"
      ]
    },
    {
      "id": "ent_145",
      "type": "PharmEffect",
      "name": "side effects",
      "attributes": {
        "context": "roflumilast-related side effects"
      },
      "source_chunk_ids": [
        "c674c321267d06ecbf909fb4707589a9"
      ]
    },
    {
      "id": "ent_146",
      "type": "Indication",
      "name": "nausea",
      "attributes": {
        "context": "consisted of nausea"
      },
      "source_chunk_ids": [
        "c674c321267d06ecbf909fb4707589a9"
      ]
    },
    {
      "id": "ent_147",
      "type": "Indication",
      "name": "diarrhea",
      "attributes": {
        "context": "diarrhea and mild weight loss"
      },
      "source_chunk_ids": [
        "c674c321267d06ecbf909fb4707589a9"
      ]
    },
    {
      "id": "ent_148",
      "type": "PharmEffect",
      "name": "mild weight loss",
      "attributes": {
        "context": "mild weight loss"
      },
      "source_chunk_ids": [
        "c674c321267d06ecbf909fb4707589a9"
      ]
    },
    {
      "id": "ent_149",
      "type": "Concentration",
      "name": "30-50%",
      "attributes": {
        "context": "reflecting a 30-50% suppression"
      },
      "source_chunk_ids": [
        "8fbd93fb1b66921dca70e07abddb636a"
      ]
    },
    {
      "id": "ent_150",
      "type": "PharmEffect",
      "name": "suppression of inflammatory cell numbers",
      "attributes": {
        "context": "30-50% suppression of inflammatory cell numbers"
      },
      "source_chunk_ids": [
        "8fbd93fb1b66921dca70e07abddb636a"
      ]
    },
    {
      "id": "ent_151",
      "type": "Concentration",
      "name": "40-50%",
      "attributes": {
        "context": "reduced ... by approximately 40-50%"
      },
      "source_chunk_ids": [
        "8fbd93fb1b66921dca70e07abddb636a"
      ]
    },
    {
      "id": "ent_152",
      "type": "PharmEffect",
      "name": "anti-inflammatory",
      "attributes": {
        "context": "an anti-inflammatory mechanism"
      },
      "source_chunk_ids": [
        "8fbd93fb1b66921dca70e07abddb636a"
      ]
    },
    {
      "id": "ent_153",
      "type": "Compound",
      "name": "cilomilast",
      "attributes": {
        "context": "cilomilast reduced the level"
      },
      "source_chunk_ids": [
        "8fbd93fb1b66921dca70e07abddb636a"
      ]
    },
    {
      "id": "ent_154",
      "type": "Compound",
      "name": "TNF-alpha",
      "attributes": {
        "context": "reduced the level of TNF-alpha"
      },
      "source_chunk_ids": [
        "8fbd93fb1b66921dca70e07abddb636a"
      ]
    },
    {
      "id": "ent_155",
      "type": "Concentration",
      "name": "25% decrease",
      "attributes": {
        "context": "TNF-alpha (25% decrease)"
      },
      "source_chunk_ids": [
        "8fbd93fb1b66921dca70e07abddb636a"
      ]
    },
    {
      "id": "ent_156",
      "type": "Compound",
      "name": "GMCSF",
      "attributes": {
        "context": "GMCSF (46% decrease)"
      },
      "source_chunk_ids": [
        "8fbd93fb1b66921dca70e07abddb636a"
      ]
    },
    {
      "id": "ent_157",
      "type": "Concentration",
      "name": "46% decrease",
      "attributes": {
        "context": "GMCSF (46% decrease)"
      },
      "source_chunk_ids": [
        "8fbd93fb1b66921dca70e07abddb636a"
      ]
    },
    {
      "id": "ent_158",
      "type": "Compound",
      "name": "neutrophil chemotactic factors",
      "attributes": {
        "context": "and neutrophil chemotactic factors"
      },
      "source_chunk_ids": [
        "8fbd93fb1b66921dca70e07abddb636a"
      ]
    },
    {
      "id": "ent_159",
      "type": "Concentration",
      "name": "35% decrease",
      "attributes": {
        "context": "factors (35% decrease)"
      },
      "source_chunk_ids": [
        "8fbd93fb1b66921dca70e07abddb636a"
      ]
    },
    {
      "id": "ent_160",
      "type": "Compound",
      "name": "IL-8",
      "attributes": {
        "context": "no effect on IL-8 released"
      },
      "source_chunk_ids": [
        "8fbd93fb1b66921dca70e07abddb636a"
      ]
    },
    {
      "id": "ent_161",
      "type": "Indication",
      "name": "COPD",
      "attributes": {
        "context": "epithelial cells from COPD patients"
      },
      "source_chunk_ids": [
        "8fbd93fb1b66921dca70e07abddb636a"
      ]
    },
    {
      "id": "ent_162",
      "type": "PharmEffect",
      "name": "inhibition of the inflammatory response",
      "attributes": {
        "context": "greater inhibition of the inflammatory response"
      },
      "source_chunk_ids": [
        "8fbd93fb1b66921dca70e07abddb636a"
      ]
    },
    {
      "id": "ent_163",
      "type": "Compound",
      "name": "ICS",
      "attributes": {
        "context": "combination therapy of ICS and LABA"
      },
      "source_chunk_ids": [
        "a4c8875444a9e50f272646ddc96fe9b4"
      ]
    },
    {
      "id": "ent_164",
      "type": "Compound",
      "name": "LABA",
      "attributes": {
        "context": "combination therapy of ICS and LABA"
      },
      "source_chunk_ids": [
        "a4c8875444a9e50f272646ddc96fe9b4"
      ]
    },
    {
      "id": "ent_165",
      "type": "PharmEffect",
      "name": "relaxation of airway smooth muscle",
      "attributes": {
        "context": "relaxation of airway smooth muscle"
      },
      "source_chunk_ids": [
        "a4c8875444a9e50f272646ddc96fe9b4"
      ]
    },
    {
      "id": "ent_166",
      "type": "PharmEffect",
      "name": "anti-inflammatory action",
      "attributes": {
        "context": "synergistic or additive anti-inflammatory action"
      },
      "source_chunk_ids": [
        "a4c8875444a9e50f272646ddc96fe9b4"
      ]
    },
    {
      "id": "ent_167",
      "type": "Compound",
      "name": "salmeterol",
      "attributes": {
        "context": "between salmeterol versus combination therapy"
      },
      "source_chunk_ids": [
        "a4c8875444a9e50f272646ddc96fe9b4"
      ]
    },
    {
      "id": "ent_168",
      "type": "PharmEffect",
      "name": "anti-inflammatory activity",
      "attributes": {
        "context": "associated with anti-inflammatory activity"
      },
      "source_chunk_ids": [
        "a4c8875444a9e50f272646ddc96fe9b4"
      ]
    },
    {
      "id": "ent_169",
      "type": "Concentration",
      "name": "12-13 weeks",
      "attributes": {
        "context": "after 12-13 weeks of treatment"
      },
      "source_chunk_ids": [
        "a4c8875444a9e50f272646ddc96fe9b4"
      ]
    },
    {
      "id": "ent_170",
      "type": "Compound",
      "name": "fluticasone",
      "attributes": {
        "context": "monotherapy with fluticasone"
      },
      "source_chunk_ids": [
        "a4c8875444a9e50f272646ddc96fe9b4"
      ]
    },
    {
      "id": "ent_171",
      "type": "Compound",
      "name": "fluticasone",
      "attributes": {
        "context": "effect of fluticasone monotherapy"
      },
      "source_chunk_ids": [
        "a4c8875444a9e50f272646ddc96fe9b4"
      ]
    },
    {
      "id": "ent_172",
      "type": "PharmEffect",
      "name": "reduction (of airway neutrophil numbers)",
      "attributes": {
        "context": "reports of a reduction [48]"
      },
      "source_chunk_ids": [
        "a4c8875444a9e50f272646ddc96fe9b4"
      ]
    },
    {
      "id": "ent_173",
      "type": "PharmEffect",
      "name": "increase (of airway neutrophil numbers)",
      "attributes": {
        "context": "and increase [52]"
      },
      "source_chunk_ids": [
        "a4c8875444a9e50f272646ddc96fe9b4"
      ]
    },
    {
      "id": "ent_174",
      "type": "PharmEffect",
      "name": "corticosteroid resistance",
      "attributes": {
        "context": "corticosteroid resistance in patients with COPD"
      },
      "source_chunk_ids": [
        "a4c8875444a9e50f272646ddc96fe9b4"
      ]
    },
    {
      "id": "ent_175",
      "type": "Indication",
      "name": "COPD",
      "attributes": {
        "context": "patients with COPD"
      },
      "source_chunk_ids": [
        "a4c8875444a9e50f272646ddc96fe9b4"
      ]
    },
    {
      "id": "ent_176",
      "type": "Compound",
      "name": "histone deacetylase (HDAC)-2",
      "attributes": {
        "context": "activity of histone deacetylase (HDAC)-2"
      },
      "source_chunk_ids": [
        "a4c8875444a9e50f272646ddc96fe9b4"
      ]
    },
    {
      "id": "ent_177",
      "type": "PharmEffect",
      "name": "reduction in the activity of histone deacetylase (HDAC)-2",
      "attributes": {
        "context": "resulting in reduction in the activity of histone deacetylase (HDAC)-2"
      },
      "source_chunk_ids": [
        "a4c8875444a9e50f272646ddc96fe9b4"
      ]
    },
    {
      "id": "ent_178",
      "type": "Compound",
      "name": "HDAC2",
      "attributes": {
        "context": "increasing the HDAC2-activity"
      },
      "source_chunk_ids": [
        "a4c8875444a9e50f272646ddc96fe9b4"
      ]
    },
    {
      "id": "ent_179",
      "type": "Compound",
      "name": "PDE-inhibitors",
      "attributes": {
        "context": "by PDE-inhibitors"
      },
      "source_chunk_ids": [
        "a4c8875444a9e50f272646ddc96fe9b4"
      ]
    },
    {
      "id": "ent_180",
      "type": "Compound",
      "name": "phosphoinositide 3 kinase-delta inhibitors",
      "attributes": {
        "context": "phosphoinositide 3 kinase-delta inhibitors"
      },
      "source_chunk_ids": [
        "a4c8875444a9e50f272646ddc96fe9b4"
      ]
    },
    {
      "id": "ent_181",
      "type": "Compound",
      "name": "macrolides",
      "attributes": {
        "context": "and macrolides"
      },
      "source_chunk_ids": [
        "a4c8875444a9e50f272646ddc96fe9b4"
      ]
    },
    {
      "id": "ent_182",
      "type": "PharmEffect",
      "name": "reversal of corticosteroid resistance",
      "attributes": {
        "context": "result in a reversal of corticosteroid resistance"
      },
      "source_chunk_ids": [
        "a4c8875444a9e50f272646ddc96fe9b4"
      ]
    },
    {
      "id": "ent_183",
      "type": "Compound",
      "name": "PDE4-inhibitors",
      "attributes": {
        "context": "systemically administered PDE4-inhibitors"
      },
      "source_chunk_ids": [
        "241527c44b0da752d04e8ae195c2b217"
      ]
    },
    {
      "id": "ent_184",
      "type": "PharmEffect",
      "name": "nausea",
      "attributes": {
        "context": "produce nausea"
      },
      "source_chunk_ids": [
        "241527c44b0da752d04e8ae195c2b217"
      ]
    },
    {
      "id": "ent_185",
      "type": "PharmEffect",
      "name": "headache",
      "attributes": {
        "context": "produce nausea and headache"
      },
      "source_chunk_ids": [
        "241527c44b0da752d04e8ae195c2b217"
      ]
    },
    {
      "id": "ent_186",
      "type": "Compound",
      "name": "cilomilast",
      "attributes": {
        "context": "shunted off cilomilast"
      },
      "source_chunk_ids": [
        "241527c44b0da752d04e8ae195c2b217"
      ]
    },
    {
      "id": "ent_187",
      "type": "Compound",
      "name": "roflumilast",
      "attributes": {
        "context": "eliminated for roflumilast"
      },
      "source_chunk_ids": [
        "241527c44b0da752d04e8ae195c2b217"
      ]
    },
    {
      "id": "ent_188",
      "type": "Compound",
      "name": "subtype-selective PDE4-inhibitors",
      "attributes": {
        "context": "develop subtype-selective PDE4-inhibitors"
      },
      "source_chunk_ids": [
        "241527c44b0da752d04e8ae195c2b217"
      ]
    },
    {
      "id": "ent_189",
      "type": "Compound",
      "name": "PDE4D isoenzymes",
      "attributes": {
        "context": "inhibition of the PDE4D isoenzymes"
      },
      "source_chunk_ids": [
        "241527c44b0da752d04e8ae195c2b217"
      ]
    },
    {
      "id": "ent_190",
      "type": "Compound",
      "name": "brain-penetrant PDE4-",
      "attributes": {
        "context": "selective brain-penetrant PDE4-"
      },
      "source_chunk_ids": [
        "241527c44b0da752d04e8ae195c2b217"
      ]
    },
    {
      "id": "ent_191",
      "type": "Compound",
      "name": "inhibitors",
      "attributes": {
        "context": "inhibitors that are devoid of emesis"
      },
      "source_chunk_ids": [
        "a5696a27958fdb2fe8dcc7c0e7c8b9e1"
      ]
    },
    {
      "id": "ent_192",
      "type": "PharmEffect",
      "name": "emesis",
      "attributes": {
        "context": "devoid of emesis"
      },
      "source_chunk_ids": [
        "a5696a27958fdb2fe8dcc7c0e7c8b9e1"
      ]
    },
    {
      "id": "ent_193",
      "type": "Compound",
      "name": "PDE4D",
      "attributes": {
        "context": "targeting of PDE4D"
      },
      "source_chunk_ids": [
        "a5696a27958fdb2fe8dcc7c0e7c8b9e1"
      ]
    },
    {
      "id": "ent_194",
      "type": "Indication",
      "name": "COPD",
      "attributes": {
        "context": "interest to COPD"
      },
      "source_chunk_ids": [
        "a5696a27958fdb2fe8dcc7c0e7c8b9e1"
      ]
    },
    {
      "id": "ent_195",
      "type": "PharmEffect",
      "name": "PDE4-inhibition",
      "attributes": {
        "context": "achieve more substantial PDE4-inhibition in the lung"
      },
      "source_chunk_ids": [
        "92ee628ff47e1bebfed8efff9dc3c924"
      ]
    },
    {
      "id": "ent_196",
      "type": "Indication",
      "name": "respiratory disease",
      "attributes": {
        "context": "evaluated in respiratory disease"
      },
      "source_chunk_ids": [
        "92ee628ff47e1bebfed8efff9dc3c924"
      ]
    },
    {
      "id": "ent_197",
      "type": "Compound",
      "name": "UK-500,001",
      "attributes": {
        "context": "A highly potent PDE4-inhibitor, UK-500,001"
      },
      "source_chunk_ids": [
        "92ee628ff47e1bebfed8efff9dc3c924"
      ]
    },
    {
      "id": "ent_198",
      "type": "Indication",
      "name": "COPD",
      "attributes": {
        "context": "patients with moderate to severe COPD"
      },
      "source_chunk_ids": [
        "92ee628ff47e1bebfed8efff9dc3c924"
      ]
    },
    {
      "id": "ent_199",
      "type": "Concentration",
      "name": "6 weeks",
      "attributes": {
        "context": "after 6 weeks of treatment"
      },
      "source_chunk_ids": [
        "92ee628ff47e1bebfed8efff9dc3c924"
      ]
    },
    {
      "id": "ent_200",
      "type": "Compound",
      "name": "GSK256066",
      "attributes": {
        "context": "the inhaled PDE4-inhibitor, GSK256066"
      },
      "source_chunk_ids": [
        "92ee628ff47e1bebfed8efff9dc3c924"
      ]
    },
    {
      "id": "ent_201",
      "type": "PharmEffect",
      "name": "attenuate the acute and late phase allergic airway response",
      "attributes": {
        "context": "was shown to attenuate the acute and late phase allergic airway response"
      },
      "source_chunk_ids": [
        "92ee628ff47e1bebfed8efff9dc3c924"
      ]
    },
    {
      "id": "ent_202",
      "type": "Concentration",
      "name": "1 week",
      "attributes": {
        "context": "after 1 week of treatment"
      },
      "source_chunk_ids": [
        "92ee628ff47e1bebfed8efff9dc3c924"
      ]
    },
    {
      "id": "ent_203",
      "type": "Indication",
      "name": "COPD",
      "attributes": {
        "context": "clinically effective in COPD"
      },
      "source_chunk_ids": [
        "92ee628ff47e1bebfed8efff9dc3c924"
      ]
    },
    {
      "id": "ent_204",
      "type": "Compound",
      "name": "mixed PDE-inhibitors",
      "attributes": {
        "context": "using mixed PDE-inhibitors"
      },
      "source_chunk_ids": [
        "efbf083d2a7a9f13233ec0b391a4ce96"
      ]
    },
    {
      "id": "ent_205",
      "type": "Indication",
      "name": "COPD",
      "attributes": {
        "context": "treatment of COPD"
      },
      "source_chunk_ids": [
        "efbf083d2a7a9f13233ec0b391a4ce96"
      ]
    },
    {
      "id": "ent_206",
      "type": "Compound",
      "name": "PDE4-inhibitors",
      "attributes": {
        "context": "that PDE4-inhibitors per se"
      },
      "source_chunk_ids": [
        "efbf083d2a7a9f13233ec0b391a4ce96"
      ]
    },
    {
      "id": "ent_207",
      "type": "PharmEffect",
      "name": "inhibiting macrophage function",
      "attributes": {
        "context": "poor at inhibiting macrophage function"
      },
      "source_chunk_ids": [
        "efbf083d2a7a9f13233ec0b391a4ce96"
      ]
    },
    {
      "id": "ent_208",
      "type": "Compound",
      "name": "PDE3",
      "attributes": {
        "context": "that PDE3 is also present"
      },
      "source_chunk_ids": [
        "efbf083d2a7a9f13233ec0b391a4ce96"
      ]
    },
    {
      "id": "ent_209",
      "type": "PharmEffect",
      "name": "bronchodilator effects",
      "attributes": {
        "context": "produce bronchodilator effects"
      },
      "source_chunk_ids": [
        "efbf083d2a7a9f13233ec0b391a4ce96"
      ]
    },
    {
      "id": "ent_210",
      "type": "PharmEffect",
      "name": "promote chloride ion secretion",
      "attributes": {
        "context": "promote chloride ion secretion"
      },
      "source_chunk_ids": [
        "efbf083d2a7a9f13233ec0b391a4ce96"
      ]
    },
    {
      "id": "ent_211",
      "type": "Compound",
      "name": "chloride ion",
      "attributes": {
        "context": "promote chloride ion secretion"
      },
      "source_chunk_ids": [
        "efbf083d2a7a9f13233ec0b391a4ce96"
      ]
    },
    {
      "id": "ent_212",
      "type": "PharmEffect",
      "name": "additive actions",
      "attributes": {
        "context": "have additive or potentially synergistic actions"
      },
      "source_chunk_ids": [
        "efbf083d2a7a9f13233ec0b391a4ce96"
      ]
    },
    {
      "id": "ent_213",
      "type": "PharmEffect",
      "name": "synergistic actions",
      "attributes": {
        "context": "potentially synergistic actions"
      },
      "source_chunk_ids": [
        "efbf083d2a7a9f13233ec0b391a4ce96"
      ]
    },
    {
      "id": "ent_214",
      "type": "Compound",
      "name": "mixed PDE3/4 inhibitors",
      "attributes": {
        "context": "early mixed PDE3/4 inhibitors"
      },
      "source_chunk_ids": [
        "efbf083d2a7a9f13233ec0b391a4ce96"
      ]
    },
    {
      "id": "ent_215",
      "type": "PharmEffect",
      "name": "anti-inflammatory activity",
      "attributes": {
        "context": "coupled with anti-inflammatory activity"
      },
      "source_chunk_ids": [
        "efbf083d2a7a9f13233ec0b391a4ce96"
      ]
    },
    {
      "id": "ent_216",
      "type": "Compound",
      "name": "PDE7",
      "attributes": {
        "context": "targeting PDE7 may also be beneficial"
      },
      "source_chunk_ids": [
        "019e08c07d722aa9b0d108941fa07228"
      ]
    },
    {
      "id": "ent_217",
      "type": "Indication",
      "name": "COPD",
      "attributes": {
        "context": "pathogenesis of COPD"
      },
      "source_chunk_ids": [
        "019e08c07d722aa9b0d108941fa07228"
      ]
    },
    {
      "id": "ent_218",
      "type": "Compound",
      "name": "chemical inhibitor",
      "attributes": {
        "context": "targeting PDE7 with a chemical inhibitor"
      },
      "source_chunk_ids": [
        "019e08c07d722aa9b0d108941fa07228"
      ]
    },
    {
      "id": "ent_219",
      "type": "PharmEffect",
      "name": "modify cell function",
      "attributes": {
        "context": "failed to modify cell function"
      },
      "source_chunk_ids": [
        "019e08c07d722aa9b0d108941fa07228"
      ]
    },
    {
      "id": "ent_220",
      "type": "PharmEffect",
      "name": "enhance the inhibitory action",
      "attributes": {
        "context": "appeared to enhance the inhibitory action"
      },
      "source_chunk_ids": [
        "019e08c07d722aa9b0d108941fa07228"
      ]
    },
    {
      "id": "ent_221",
      "type": "Compound",
      "name": "PDE4 selective inhibitor",
      "attributes": {
        "context": "inhibitory action of a PDE4 selective inhibitor"
      },
      "source_chunk_ids": [
        "019e08c07d722aa9b0d108941fa07228"
      ]
    },
    {
      "id": "ent_222",
      "type": "Compound",
      "name": "PDE4",
      "attributes": {
        "context": "Targeting both PDE4 and PDE7"
      },
      "source_chunk_ids": [
        "019e08c07d722aa9b0d108941fa07228"
      ]
    },
    {
      "id": "ent_223",
      "type": "Compound",
      "name": "PDE7",
      "attributes": {
        "context": "Targeting both PDE4 and PDE7"
      },
      "source_chunk_ids": [
        "019e08c07d722aa9b0d108941fa07228"
      ]
    },
    {
      "id": "ent_224",
      "type": "Compound",
      "name": "antisense oligonucleotides",
      "attributes": {
        "context": "PDE7 with antisense oligonucleotides"
      },
      "source_chunk_ids": [
        "019e08c07d722aa9b0d108941fa07228"
      ]
    },
    {
      "id": "ent_225",
      "type": "PharmEffect",
      "name": "suppressed various indices of airway inflammation",
      "attributes": {
        "context": "suppressed various indices of airway inflammation"
      },
      "source_chunk_ids": [
        "019e08c07d722aa9b0d108941fa07228"
      ]
    },
    {
      "id": "ent_226",
      "type": "Indication",
      "name": "airway inflammation",
      "attributes": {
        "context": "indices of airway inflammation"
      },
      "source_chunk_ids": [
        "019e08c07d722aa9b0d108941fa07228"
      ]
    },
    {
      "id": "ent_227",
      "type": "Compound",
      "name": "oligonucleotides",
      "attributes": {
        "context": "component oligonucleotides"
      },
      "source_chunk_ids": [
        "fb3aee050dcc2b237b5adb8e4c8661de"
      ]
    },
    {
      "id": "ent_228",
      "type": "PharmEffect",
      "name": "inhibitory activity",
      "attributes": {
        "context": "provided a greater inhibitory activity"
      },
      "source_chunk_ids": [
        "fb3aee050dcc2b237b5adb8e4c8661de"
      ]
    },
    {
      "id": "ent_229",
      "type": "Compound",
      "name": "PDE-inhibitors",
      "attributes": {
        "context": "development of mixed PDE-inhibitors"
      },
      "source_chunk_ids": [
        "fb3aee050dcc2b237b5adb8e4c8661de"
      ]
    },
    {
      "id": "ent_230",
      "type": "Indication",
      "name": "COPD",
      "attributes": {
        "context": "treatment of COPD"
      },
      "source_chunk_ids": [
        "fb3aee050dcc2b237b5adb8e4c8661de"
      ]
    },
    {
      "id": "ent_231",
      "type": "Compound",
      "name": "theophylline",
      "attributes": {
        "context": "PDE-inhibitor theophylline"
      },
      "source_chunk_ids": [
        "fd7aebf77c1caac407be5ee5c8a6a308"
      ]
    },
    {
      "id": "ent_232",
      "type": "PharmEffect",
      "name": "PDE-inhibitor",
      "attributes": {
        "context": "non-selective PDE-inhibitor theophylline"
      },
      "source_chunk_ids": [
        "fd7aebf77c1caac407be5ee5c8a6a308"
      ]
    },
    {
      "id": "ent_233",
      "type": "Compound",
      "name": "cilomilast",
      "attributes": {
        "context": "PDE4-inhibitors cilomilast"
      },
      "source_chunk_ids": [
        "fd7aebf77c1caac407be5ee5c8a6a308"
      ]
    },
    {
      "id": "ent_234",
      "type": "Compound",
      "name": "roflumilast",
      "attributes": {
        "context": "PDE4-inhibitors cilomilast and roflumilast"
      },
      "source_chunk_ids": [
        "fd7aebf77c1caac407be5ee5c8a6a308"
      ]
    },
    {
      "id": "ent_235",
      "type": "PharmEffect",
      "name": "PDE4-inhibitors",
      "attributes": {
        "context": "selective PDE4-inhibitors cilomilast and roflumilast"
      },
      "source_chunk_ids": [
        "fd7aebf77c1caac407be5ee5c8a6a308"
      ]
    },
    {
      "id": "ent_236",
      "type": "PharmEffect",
      "name": "side effects",
      "attributes": {
        "context": "cause substantially less side effects"
      },
      "source_chunk_ids": [
        "fd7aebf77c1caac407be5ee5c8a6a308"
      ]
    },
    {
      "id": "ent_237",
      "type": "Compound",
      "name": "roflumilast",
      "attributes": {
        "context": "roflumilast-related adverse events"
      },
      "source_chunk_ids": [
        "fd7aebf77c1caac407be5ee5c8a6a308"
      ]
    },
    {
      "id": "ent_238",
      "type": "PharmEffect",
      "name": "adverse events",
      "attributes": {
        "context": "roflumilast-related adverse events"
      },
      "source_chunk_ids": [
        "fd7aebf77c1caac407be5ee5c8a6a308"
      ]
    },
    {
      "id": "ent_239",
      "type": "Indication",
      "name": "COPD",
      "attributes": {
        "context": "reported by COPD-patients"
      },
      "source_chunk_ids": [
        "fd7aebf77c1caac407be5ee5c8a6a308"
      ]
    },
    {
      "id": "ent_240",
      "type": "PharmEffect",
      "name": "adverse events",
      "attributes": {
        "context": "central adverse events"
      },
      "source_chunk_ids": [
        "fd7aebf77c1caac407be5ee5c8a6a308"
      ]
    },
    {
      "id": "ent_241",
      "type": "PharmEffect",
      "name": "nausea",
      "attributes": {
        "context": "(nausea, headache, insomnia)"
      },
      "source_chunk_ids": [
        "fd7aebf77c1caac407be5ee5c8a6a308"
      ]
    },
    {
      "id": "ent_242",
      "type": "PharmEffect",
      "name": "headache",
      "attributes": {
        "context": "(nausea, headache, insomnia)"
      },
      "source_chunk_ids": [
        "fd7aebf77c1caac407be5ee5c8a6a308"
      ]
    },
    {
      "id": "ent_243",
      "type": "PharmEffect",
      "name": "insomnia",
      "attributes": {
        "context": "(nausea, headache, insomnia)"
      },
      "source_chunk_ids": [
        "fd7aebf77c1caac407be5ee5c8a6a308"
      ]
    },
    {
      "id": "ent_244",
      "type": "PharmEffect",
      "name": "gastro-intestinal side effects",
      "attributes": {
        "context": "gastro-intestinal side effects (diarrhea)"
      },
      "source_chunk_ids": [
        "fd7aebf77c1caac407be5ee5c8a6a308"
      ]
    },
    {
      "id": "ent_245",
      "type": "PharmEffect",
      "name": "diarrhea",
      "attributes": {
        "context": "gastro-intestinal side effects (diarrhea)"
      },
      "source_chunk_ids": [
        "fd7aebf77c1caac407be5ee5c8a6a308"
      ]
    },
    {
      "id": "ent_246",
      "type": "PharmEffect",
      "name": "weight loss",
      "attributes": {
        "context": "(modest) weight loss"
      },
      "source_chunk_ids": [
        "fd7aebf77c1caac407be5ee5c8a6a308"
      ]
    },
    {
      "id": "ent_247",
      "type": "PharmEffect",
      "name": "Adverse events",
      "attributes": {
        "context": "Adverse events mostly became evident"
      },
      "source_chunk_ids": [
        "fd7aebf77c1caac407be5ee5c8a6a308"
      ]
    },
    {
      "id": "ent_248",
      "type": "Compound",
      "name": "roflumilast",
      "attributes": {
        "context": "patient withdrawal in the roflumilast-arms"
      },
      "source_chunk_ids": [
        "fd7aebf77c1caac407be5ee5c8a6a308"
      ]
    },
    {
      "id": "ent_249",
      "type": "PharmEffect",
      "name": "cardiac toxicity",
      "attributes": {
        "context": "no clinically relevant cardiac toxicity"
      },
      "source_chunk_ids": [
        "fd7aebf77c1caac407be5ee5c8a6a308"
      ]
    },
    {
      "id": "ent_250",
      "type": "Indication",
      "name": "diarrhea",
      "attributes": {
        "context": "the most common side effects were diarrhea and weight loss"
      },
      "source_chunk_ids": [
        "5924c502444e71f851db89ce6bbf22a9"
      ]
    },
    {
      "id": "ent_251",
      "type": "PharmEffect",
      "name": "weight loss",
      "attributes": {
        "context": "the most common side effects were diarrhea and weight loss"
      },
      "source_chunk_ids": [
        "5924c502444e71f851db89ce6bbf22a9"
      ]
    },
    {
      "id": "ent_252",
      "type": "Compound",
      "name": "roflumilast",
      "attributes": {
        "context": "67% in the roflumilast arm"
      },
      "source_chunk_ids": [
        "5924c502444e71f851db89ce6bbf22a9"
      ]
    },
    {
      "id": "ent_253",
      "type": "PharmEffect",
      "name": "weight loss",
      "attributes": {
        "context": "weight loss was reported, with a mean of 2.1 kg"
      },
      "source_chunk_ids": [
        "5924c502444e71f851db89ce6bbf22a9"
      ]
    },
    {
      "id": "ent_254",
      "type": "Concentration",
      "name": "2.1 kg",
      "attributes": {
        "context": "with a mean of 2.1 kg"
      },
      "source_chunk_ids": [
        "5924c502444e71f851db89ce6bbf22a9"
      ]
    },
    {
      "id": "ent_255",
      "type": "Concentration",
      "name": "2.0 kg",
      "attributes": {
        "context": "similar mean weight loss of 2.0 and 1.8 kg"
      },
      "source_chunk_ids": [
        "5924c502444e71f851db89ce6bbf22a9"
      ]
    },
    {
      "id": "ent_256",
      "type": "Concentration",
      "name": "1.8 kg",
      "attributes": {
        "context": "similar mean weight loss of 2.0 and 1.8 kg"
      },
      "source_chunk_ids": [
        "5924c502444e71f851db89ce6bbf22a9"
      ]
    },
    {
      "id": "ent_257",
      "type": "PharmEffect",
      "name": "weight loss",
      "attributes": {
        "context": "The largest absolute weight loss was seen"
      },
      "source_chunk_ids": [
        "5924c502444e71f851db89ce6bbf22a9"
      ]
    },
    {
      "id": "ent_258",
      "type": "Indication",
      "name": "BMI >30",
      "attributes": {
        "context": "patients with a BMI >30"
      },
      "source_chunk_ids": [
        "5924c502444e71f851db89ce6bbf22a9"
      ]
    },
    {
      "id": "ent_259",
      "type": "PharmEffect",
      "name": "weight loss",
      "attributes": {
        "context": "this weight loss could be ascribed primarily to fat loss"
      },
      "source_chunk_ids": [
        "5924c502444e71f851db89ce6bbf22a9"
      ]
    },
    {
      "id": "ent_260",
      "type": "PharmEffect",
      "name": "fat loss",
      "attributes": {
        "context": "ascribed primarily to fat loss"
      },
      "source_chunk_ids": [
        "5924c502444e71f851db89ce6bbf22a9"
      ]
    },
    {
      "id": "ent_261",
      "type": "PharmEffect",
      "name": "anti-inflammatory",
      "attributes": {
        "context": "systemic anti-inflammatory potential of roflumilast"
      },
      "source_chunk_ids": [
        "5924c502444e71f851db89ce6bbf22a9"
      ]
    },
    {
      "id": "ent_262",
      "type": "Compound",
      "name": "roflumilast",
      "attributes": {
        "context": "potential of roflumilast"
      },
      "source_chunk_ids": [
        "5924c502444e71f851db89ce6bbf22a9"
      ]
    },
    {
      "id": "ent_263",
      "type": "Indication",
      "name": "COPD",
      "attributes": {
        "context": "In the COPD safety pooled analysis"
      },
      "source_chunk_ids": [
        "a1f64eddcf4fe4ff7c23eb53177b72df"
      ]
    },
    {
      "id": "ent_264",
      "type": "Indication",
      "name": "COPD",
      "attributes": {
        "context": "12,000 COPD patients"
      },
      "source_chunk_ids": [
        "a1f64eddcf4fe4ff7c23eb53177b72df"
      ]
    },
    {
      "id": "ent_265",
      "type": "Compound",
      "name": "roflumilast",
      "attributes": {
        "context": "patients on roflumilast 250 \u00b5g"
      },
      "source_chunk_ids": [
        "a1f64eddcf4fe4ff7c23eb53177b72df"
      ]
    },
    {
      "id": "ent_266",
      "type": "Concentration",
      "name": "250 \u00b5g",
      "attributes": {
        "context": "roflumilast 250 \u00b5g"
      },
      "source_chunk_ids": [
        "a1f64eddcf4fe4ff7c23eb53177b72df"
      ]
    },
    {
      "id": "ent_267",
      "type": "Compound",
      "name": "roflumilast",
      "attributes": {
        "context": "patients on roflumilast 500 \u00b5g"
      },
      "source_chunk_ids": [
        "a1f64eddcf4fe4ff7c23eb53177b72df"
      ]
    },
    {
      "id": "ent_268",
      "type": "Concentration",
      "name": "500 \u00b5g",
      "attributes": {
        "context": "roflumilast 500 \u00b5g"
      },
      "source_chunk_ids": [
        "a1f64eddcf4fe4ff7c23eb53177b72df"
      ]
    },
    {
      "id": "ent_269",
      "type": "Compound",
      "name": "placebo",
      "attributes": {
        "context": "patients on placebo"
      },
      "source_chunk_ids": [
        "a1f64eddcf4fe4ff7c23eb53177b72df"
      ]
    },
    {
      "id": "ent_270",
      "type": "PharmEffect",
      "name": "suicides",
      "attributes": {
        "context": "3 cases of suicides were reported"
      },
      "source_chunk_ids": [
        "a1f64eddcf4fe4ff7c23eb53177b72df"
      ]
    },
    {
      "id": "ent_271",
      "type": "Compound",
      "name": "roflumilast",
      "attributes": {
        "context": "receiving roflumilast treatment"
      },
      "source_chunk_ids": [
        "a1f64eddcf4fe4ff7c23eb53177b72df"
      ]
    },
    {
      "id": "ent_272",
      "type": "Concentration",
      "name": "250 \u00b5g",
      "attributes": {
        "context": "1 on 250 \u00b5g"
      },
      "source_chunk_ids": [
        "a1f64eddcf4fe4ff7c23eb53177b72df"
      ]
    },
    {
      "id": "ent_273",
      "type": "Concentration",
      "name": "500 \u00b5g",
      "attributes": {
        "context": "2 on 500 \u00b5g"
      },
      "source_chunk_ids": [
        "a1f64eddcf4fe4ff7c23eb53177b72df"
      ]
    },
    {
      "id": "ent_274",
      "type": "Indication",
      "name": "depression",
      "attributes": {
        "context": "pre-existent depression among these patients"
      },
      "source_chunk_ids": [
        "a1f64eddcf4fe4ff7c23eb53177b72df"
      ]
    },
    {
      "id": "ent_275",
      "type": "Indication",
      "name": "COPD",
      "attributes": {
        "context": "among COPD patients"
      },
      "source_chunk_ids": [
        "19cd1e480f56ae223d1eff50703111e3"
      ]
    },
    {
      "id": "ent_276",
      "type": "PharmEffect",
      "name": "anti-inflammatory",
      "attributes": {
        "context": "anti-inflammatory effects"
      },
      "source_chunk_ids": [
        "53dd7d4526a10744248aa8069e1e8ff7"
      ]
    },
    {
      "id": "ent_277",
      "type": "Compound",
      "name": "roflumilast",
      "attributes": {
        "context": "effects of roflumilast"
      },
      "source_chunk_ids": [
        "53dd7d4526a10744248aa8069e1e8ff7"
      ]
    },
    {
      "id": "ent_278",
      "type": "Indication",
      "name": "COPD",
      "attributes": {
        "context": "roflumilast in COPD"
      },
      "source_chunk_ids": [
        "53dd7d4526a10744248aa8069e1e8ff7"
      ]
    },
    {
      "id": "ent_279",
      "type": "Compound",
      "name": "PDE4-inhibitors",
      "attributes": {
        "context": "PDE4-inhibitors reverse"
      },
      "source_chunk_ids": [
        "53dd7d4526a10744248aa8069e1e8ff7"
      ]
    },
    {
      "id": "ent_280",
      "type": "Indication",
      "name": "corticosteroid resistance",
      "attributes": {
        "context": "reverse corticosteroid resistance"
      },
      "source_chunk_ids": [
        "53dd7d4526a10744248aa8069e1e8ff7"
      ]
    },
    {
      "id": "ent_281",
      "type": "Compound",
      "name": "PDE4-inhibitors",
      "attributes": {
        "context": "do PDE4-inhibitors"
      },
      "source_chunk_ids": [
        "53dd7d4526a10744248aa8069e1e8ff7"
      ]
    },
    {
      "id": "ent_282",
      "type": "Compound",
      "name": "ICS",
      "attributes": {
        "context": "combination with ICS"
      },
      "source_chunk_ids": [
        "53dd7d4526a10744248aa8069e1e8ff7"
      ]
    },
    {
      "id": "ent_283",
      "type": "PharmEffect",
      "name": "disease-modifying properties",
      "attributes": {
        "context": "possess disease-modifying properties"
      },
      "source_chunk_ids": [
        "53dd7d4526a10744248aa8069e1e8ff7"
      ]
    },
    {
      "id": "ent_284",
      "type": "PharmEffect",
      "name": "prevention of the increased decline in lung function",
      "attributes": {
        "context": "prevention of the increased decline in lung function"
      },
      "source_chunk_ids": [
        "53dd7d4526a10744248aa8069e1e8ff7"
      ]
    },
    {
      "id": "ent_285",
      "type": "PharmEffect",
      "name": "modulation of the systemic effects",
      "attributes": {
        "context": "modulation of the systemic effects in COPD"
      },
      "source_chunk_ids": [
        "53dd7d4526a10744248aa8069e1e8ff7"
      ]
    },
    {
      "id": "ent_286",
      "type": "Indication",
      "name": "COPD",
      "attributes": {
        "context": "systemic effects in COPD"
      },
      "source_chunk_ids": [
        "53dd7d4526a10744248aa8069e1e8ff7"
      ]
    },
    {
      "id": "ent_287",
      "type": "Compound",
      "name": "PDE4-inhibitors",
      "attributes": {
        "context": "combinations with) PDE4-inhibitors"
      },
      "source_chunk_ids": [
        "53dd7d4526a10744248aa8069e1e8ff7"
      ]
    },
    {
      "id": "ent_288",
      "type": "PharmEffect",
      "name": "decrease the morbidity",
      "attributes": {
        "context": "decrease the morbidity"
      },
      "source_chunk_ids": [
        "53dd7d4526a10744248aa8069e1e8ff7"
      ]
    },
    {
      "id": "ent_289",
      "type": "PharmEffect",
      "name": "decrease the mortality",
      "attributes": {
        "context": "decrease the morbidity and mortality"
      },
      "source_chunk_ids": [
        "53dd7d4526a10744248aa8069e1e8ff7"
      ]
    },
    {
      "id": "ent_290",
      "type": "Indication",
      "name": "COPD",
      "attributes": {
        "context": "phenotypes of) COPD"
      },
      "source_chunk_ids": [
        "53dd7d4526a10744248aa8069e1e8ff7"
      ]
    },
    {
      "id": "ent_291",
      "type": "Compound",
      "name": "roflumilast",
      "attributes": {
        "context": "combinations of) roflumilast"
      },
      "source_chunk_ids": [
        "110c0f090ab3d12c1bfab80acc2e6228"
      ]
    },
    {
      "id": "ent_292",
      "type": "Compound",
      "name": "ICS",
      "attributes": {
        "context": "roflumilast and ICS"
      },
      "source_chunk_ids": [
        "110c0f090ab3d12c1bfab80acc2e6228"
      ]
    },
    {
      "id": "ent_293",
      "type": "Indication",
      "name": "COPD",
      "attributes": {
        "context": "COPD phenotypes"
      },
      "source_chunk_ids": [
        "110c0f090ab3d12c1bfab80acc2e6228"
      ]
    },
    {
      "id": "ent_294",
      "type": "PharmEffect",
      "name": "preventive potential",
      "attributes": {
        "context": "test its preventive potential"
      },
      "source_chunk_ids": [
        "110c0f090ab3d12c1bfab80acc2e6228"
      ]
    },
    {
      "id": "ent_295",
      "type": "Indication",
      "name": "COPD",
      "attributes": {
        "context": "pharmacological COPD management"
      },
      "source_chunk_ids": [
        "110c0f090ab3d12c1bfab80acc2e6228"
      ]
    },
    {
      "id": "ent_296",
      "type": "PharmEffect",
      "name": "bronchoreversibility",
      "attributes": {
        "context": "correlates of bronchoreversibility"
      },
      "source_chunk_ids": [
        "f21327c668f6aba21135e4efc8270b3d"
      ]
    },
    {
      "id": "ent_297",
      "type": "Indication",
      "name": "emphysema",
      "attributes": {
        "context": "severe emphysema"
      },
      "source_chunk_ids": [
        "f21327c668f6aba21135e4efc8270b3d"
      ]
    },
    {
      "id": "ent_298",
      "type": "Indication",
      "name": "Chronic Obstructive Pulmonary Disease",
      "attributes": {
        "context": "Prevention of Chronic Obstructive Pulmonary Disease"
      },
      "source_chunk_ids": [
        "f21327c668f6aba21135e4efc8270b3d"
      ]
    },
    {
      "id": "ent_299",
      "type": "Indication",
      "name": "small-airway obstruction",
      "attributes": {
        "context": "nature of small-airway obstruction"
      },
      "source_chunk_ids": [
        "f21327c668f6aba21135e4efc8270b3d"
      ]
    },
    {
      "id": "ent_300",
      "type": "Indication",
      "name": "chronic obstructive pulmonary disease",
      "attributes": {
        "context": "obstruction in chronic obstructive pulmonary disease"
      },
      "source_chunk_ids": [
        "f21327c668f6aba21135e4efc8270b3d"
      ]
    },
    {
      "id": "ent_301",
      "type": "Indication",
      "name": "chronic obstructive pulmonary disease",
      "attributes": {
        "context": "Mediators of chronic obstructive pulmonary disease"
      },
      "source_chunk_ids": [
        "f21327c668f6aba21135e4efc8270b3d"
      ]
    },
    {
      "id": "ent_302",
      "type": "Indication",
      "name": "asthma",
      "attributes": {
        "context": "network in asthma"
      },
      "source_chunk_ids": [
        "f21327c668f6aba21135e4efc8270b3d"
      ]
    },
    {
      "id": "ent_303",
      "type": "Indication",
      "name": "chronic obstructive pulmonary disease",
      "attributes": {
        "context": "asthma and chronic obstructive pulmonary disease"
      },
      "source_chunk_ids": [
        "f21327c668f6aba21135e4efc8270b3d"
      ]
    },
    {
      "id": "ent_304",
      "type": "Indication",
      "name": "chronic obstructive pulmonary disease",
      "attributes": {
        "context": "cells and chronic obstructive pulmonary disease"
      },
      "source_chunk_ids": [
        "f21327c668f6aba21135e4efc8270b3d"
      ]
    },
    {
      "id": "ent_305",
      "type": "Indication",
      "name": "Systemic inflammation",
      "attributes": {
        "context": "Systemic inflammation and comorbidity"
      },
      "source_chunk_ids": [
        "f21327c668f6aba21135e4efc8270b3d"
      ]
    },
    {
      "id": "ent_306",
      "type": "Indication",
      "name": "comorbidity",
      "attributes": {
        "context": "inflammation and comorbidity in COPD"
      },
      "source_chunk_ids": [
        "f21327c668f6aba21135e4efc8270b3d"
      ]
    },
    {
      "id": "ent_307",
      "type": "Indication",
      "name": "COPD",
      "attributes": {
        "context": "comorbidity in COPD"
      },
      "source_chunk_ids": [
        "f21327c668f6aba21135e4efc8270b3d"
      ]
    },
    {
      "id": "ent_308",
      "type": "Compound",
      "name": "corticosteroids",
      "attributes": {
        "context": "inhaled corticosteroids"
      },
      "source_chunk_ids": [
        "f21327c668f6aba21135e4efc8270b3d"
      ]
    },
    {
      "id": "ent_309",
      "type": "Indication",
      "name": "chronic obstructive pulmonary disease",
      "attributes": {
        "context": "corticosteroids in chronic obstructive pulmonary disease"
      },
      "source_chunk_ids": [
        "f21327c668f6aba21135e4efc8270b3d"
      ]
    },
    {
      "id": "ent_310",
      "type": "Indication",
      "name": "COPD",
      "attributes": {
        "context": "Patients with COPD"
      },
      "source_chunk_ids": [
        "f21327c668f6aba21135e4efc8270b3d"
      ]
    },
    {
      "id": "ent_311",
      "type": "Compound",
      "name": "PDE4",
      "attributes": {
        "context": "approach against PDE4"
      },
      "source_chunk_ids": [
        "852cf327078a543563d0bbb0fbd1ce4f"
      ]
    },
    {
      "id": "ent_312",
      "type": "Compound",
      "name": "PDE7",
      "attributes": {
        "context": "and PDE7 reduces"
      },
      "source_chunk_ids": [
        "852cf327078a543563d0bbb0fbd1ce4f"
      ]
    },
    {
      "id": "ent_313",
      "type": "PharmEffect",
      "name": "reduces lung inflammation",
      "attributes": {
        "context": "reduces smoke-induced lung inflammation"
      },
      "source_chunk_ids": [
        "852cf327078a543563d0bbb0fbd1ce4f"
      ]
    },
    {
      "id": "ent_314",
      "type": "Indication",
      "name": "lung inflammation",
      "attributes": {
        "context": "smoke-induced lung inflammation"
      },
      "source_chunk_ids": [
        "852cf327078a543563d0bbb0fbd1ce4f"
      ]
    },
    {
      "id": "ent_315",
      "type": "Compound",
      "name": "phosphodiesterase 4 inhibitor",
      "attributes": {
        "context": "the phosphodiesterase 4 inhibitor, cilomilast"
      },
      "source_chunk_ids": [
        "1a23212ad32defc30b5b3252ee96f4b2"
      ]
    },
    {
      "id": "ent_316",
      "type": "Compound",
      "name": "cilomilast",
      "attributes": {
        "context": "the phosphodiesterase 4 inhibitor, cilomilast (15 mg)"
      },
      "source_chunk_ids": [
        "1a23212ad32defc30b5b3252ee96f4b2"
      ]
    },
    {
      "id": "ent_317",
      "type": "Concentration",
      "name": "single dose",
      "attributes": {
        "context": "Does a single dose of the phosphodiesterase 4 inhibitor"
      },
      "source_chunk_ids": [
        "1a23212ad32defc30b5b3252ee96f4b2"
      ]
    },
    {
      "id": "ent_318",
      "type": "Concentration",
      "name": "15 mg",
      "attributes": {
        "context": "cilomilast (15 mg)"
      },
      "source_chunk_ids": [
        "1a23212ad32defc30b5b3252ee96f4b2"
      ]
    },
    {
      "id": "ent_319",
      "type": "PharmEffect",
      "name": "bronchodilation",
      "attributes": {
        "context": "induce bronchodilation in patients"
      },
      "source_chunk_ids": [
        "1a23212ad32defc30b5b3252ee96f4b2"
      ]
    },
    {
      "id": "ent_320",
      "type": "Indication",
      "name": "chronic obstructive pulmonary disease",
      "attributes": {
        "context": "patients with chronic obstructive pulmonary disease"
      },
      "source_chunk_ids": [
        "1a23212ad32defc30b5b3252ee96f4b2"
      ]
    },
    {
      "id": "ent_321",
      "type": "Compound",
      "name": "Phosphodiesterase isozymes",
      "attributes": {
        "context": "Phosphodiesterase isozymes modulating inherent tone"
      },
      "source_chunk_ids": [
        "59dc58c6e7f2d089a9f39db1e2ada317"
      ]
    },
    {
      "id": "ent_322",
      "type": "PharmEffect",
      "name": "modulating inherent tone",
      "attributes": {
        "context": "modulating inherent tone in human airways"
      },
      "source_chunk_ids": [
        "59dc58c6e7f2d089a9f39db1e2ada317"
      ]
    },
    {
      "id": "ent_323",
      "type": "Compound",
      "name": "phosphodiesterase isozymes",
      "attributes": {
        "context": "functional role of phosphodiesterase isozymes in human airway smooth muscle"
      },
      "source_chunk_ids": [
        "72c4c562d6f1298f0247a37cdea5be1c"
      ]
    },
    {
      "id": "ent_324",
      "type": "Compound",
      "name": "phosphodiesterase 4 inhibitor",
      "attributes": {
        "context": "the phosphodiesterase 4 inhibitor"
      },
      "source_chunk_ids": [
        "17c1ee2f2ae3cf1232090ce9cf825084"
      ]
    },
    {
      "id": "ent_325",
      "type": "Compound",
      "name": "cilomilast",
      "attributes": {
        "context": "cilomilast (15 mg)"
      },
      "source_chunk_ids": [
        "17c1ee2f2ae3cf1232090ce9cf825084"
      ]
    },
    {
      "id": "ent_326",
      "type": "Concentration",
      "name": "single dose",
      "attributes": {
        "context": "Does a single dose"
      },
      "source_chunk_ids": [
        "17c1ee2f2ae3cf1232090ce9cf825084"
      ]
    },
    {
      "id": "ent_327",
      "type": "Concentration",
      "name": "15 mg",
      "attributes": {
        "context": "cilomilast (15 mg)"
      },
      "source_chunk_ids": [
        "17c1ee2f2ae3cf1232090ce9cf825084"
      ]
    },
    {
      "id": "ent_328",
      "type": "PharmEffect",
      "name": "bronchodilation",
      "attributes": {
        "context": "induce bronchodilation"
      },
      "source_chunk_ids": [
        "17c1ee2f2ae3cf1232090ce9cf825084"
      ]
    },
    {
      "id": "ent_329",
      "type": "Indication",
      "name": "chronic obstructive pulmonary disease",
      "attributes": {
        "context": "patients with chronic obstructive pulmonary disease"
      },
      "source_chunk_ids": [
        "17c1ee2f2ae3cf1232090ce9cf825084"
      ]
    },
    {
      "id": "ent_330",
      "type": "PharmEffect",
      "name": "activation",
      "attributes": {
        "context": "Dynamic activation of cystic fibrosis transmembrane conductance regulator"
      },
      "source_chunk_ids": [
        "11a44f329fcd36113c0e17e623392e5b"
      ]
    },
    {
      "id": "ent_331",
      "type": "Indication",
      "name": "cystic fibrosis",
      "attributes": {
        "context": "Dynamic activation of cystic fibrosis transmembrane conductance regulator"
      },
      "source_chunk_ids": [
        "11a44f329fcd36113c0e17e623392e5b"
      ]
    },
    {
      "id": "ent_332",
      "type": "Compound",
      "name": "phosphodiesterase inhibitors",
      "attributes": {
        "context": "type 3 and type 4D phosphodiesterase inhibitors"
      },
      "source_chunk_ids": [
        "11a44f329fcd36113c0e17e623392e5b"
      ]
    },
    {
      "id": "ent_333",
      "type": "Compound",
      "name": "type 3 phosphodiesterase inhibitors",
      "attributes": {
        "context": "type 3 and type 4D phosphodiesterase inhibitors"
      },
      "source_chunk_ids": [
        "11a44f329fcd36113c0e17e623392e5b"
      ]
    },
    {
      "id": "ent_334",
      "type": "Compound",
      "name": "type 4D phosphodiesterase inhibitors",
      "attributes": {
        "context": "type 3 and type 4D phosphodiesterase inhibitors"
      },
      "source_chunk_ids": [
        "11a44f329fcd36113c0e17e623392e5b"
      ]
    },
    {
      "id": "ent_335",
      "type": "Compound",
      "name": "phosphodiesterase inhibitors",
      "attributes": {
        "context": "selective phosphodiesterase inhibitors on mucociliary activity"
      },
      "source_chunk_ids": [
        "c49b4d51cc23f718748f08945558e701"
      ]
    },
    {
      "id": "ent_336",
      "type": "Compound",
      "name": "Phosphodiesterase 4",
      "attributes": {
        "context": "Phosphodiesterase 4 inhibition decreases MUC5AC expression"
      },
      "source_chunk_ids": [
        "c49b4d51cc23f718748f08945558e701"
      ]
    },
    {
      "id": "ent_337",
      "type": "Compound",
      "name": "MUC5AC",
      "attributes": {
        "context": "decreases MUC5AC expression induced by epidermal growth factor"
      },
      "source_chunk_ids": [
        "c49b4d51cc23f718748f08945558e701"
      ]
    },
    {
      "id": "ent_338",
      "type": "Compound",
      "name": "epidermal growth factor",
      "attributes": {
        "context": "MUC5AC expression induced by epidermal growth factor"
      },
      "source_chunk_ids": [
        "c49b4d51cc23f718748f08945558e701"
      ]
    },
    {
      "id": "ent_339",
      "type": "Compound",
      "name": "cilomilast",
      "attributes": {
        "context": "efficacy and safety of cilomilast in COPD"
      },
      "source_chunk_ids": [
        "c49b4d51cc23f718748f08945558e701"
      ]
    },
    {
      "id": "ent_340",
      "type": "Compound",
      "name": "roflumilast",
      "attributes": {
        "context": "pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor"
      },
      "source_chunk_ids": [
        "c49b4d51cc23f718748f08945558e701"
      ]
    },
    {
      "id": "ent_341",
      "type": "Compound",
      "name": "phosphodiesterase 4 inhibitor",
      "attributes": {
        "context": "a selective, oral phosphodiesterase 4 inhibitor"
      },
      "source_chunk_ids": [
        "c49b4d51cc23f718748f08945558e701"
      ]
    },
    {
      "id": "ent_342",
      "type": "PharmEffect",
      "name": "mucociliary activity",
      "attributes": {
        "context": "effect of selective phosphodiesterase inhibitors on mucociliary activity"
      },
      "source_chunk_ids": [
        "c49b4d51cc23f718748f08945558e701"
      ]
    },
    {
      "id": "ent_343",
      "type": "PharmEffect",
      "name": "inhibition",
      "attributes": {
        "context": "Phosphodiesterase 4 inhibition decreases MUC5AC expression"
      },
      "source_chunk_ids": [
        "c49b4d51cc23f718748f08945558e701"
      ]
    },
    {
      "id": "ent_344",
      "type": "PharmEffect",
      "name": "decreases MUC5AC expression",
      "attributes": {
        "context": "inhibition decreases MUC5AC expression induced by epidermal growth factor"
      },
      "source_chunk_ids": [
        "c49b4d51cc23f718748f08945558e701"
      ]
    },
    {
      "id": "ent_345",
      "type": "PharmEffect",
      "name": "selective",
      "attributes": {
        "context": "a selective, oral phosphodiesterase 4 inhibitor"
      },
      "source_chunk_ids": [
        "c49b4d51cc23f718748f08945558e701"
      ]
    },
    {
      "id": "ent_346",
      "type": "PharmEffect",
      "name": "oral",
      "attributes": {
        "context": "a selective, oral phosphodiesterase 4 inhibitor"
      },
      "source_chunk_ids": [
        "c49b4d51cc23f718748f08945558e701"
      ]
    },
    {
      "id": "ent_347",
      "type": "PharmEffect",
      "name": "anti-inflammatory",
      "attributes": {
        "context": "Roflumilast--an oral anti-inflammatory treatment"
      },
      "source_chunk_ids": [
        "c49b4d51cc23f718748f08945558e701"
      ]
    },
    {
      "id": "ent_348",
      "type": "Indication",
      "name": "COPD",
      "attributes": {
        "context": "cilomilast in COPD"
      },
      "source_chunk_ids": [
        "c49b4d51cc23f718748f08945558e701"
      ]
    },
    {
      "id": "ent_349",
      "type": "Indication",
      "name": "chronic obstructive pulmonary disease",
      "attributes": {
        "context": "development for chronic obstructive pulmonary disease"
      },
      "source_chunk_ids": [
        "c49b4d51cc23f718748f08945558e701"
      ]
    },
    {
      "id": "ent_350",
      "type": "Indication",
      "name": "severe chronic obstructive pulmonary disease",
      "attributes": {
        "context": "roflumilast in severe chronic obstructive pulmonary disease"
      },
      "source_chunk_ids": [
        "c49b4d51cc23f718748f08945558e701"
      ]
    },
    {
      "id": "ent_351",
      "type": "Indication",
      "name": "symptomatic chronic obstructive pulmonary disease",
      "attributes": {
        "context": "Roflumilast in symptomatic chronic obstructive pulmonary disease"
      },
      "source_chunk_ids": [
        "c49b4d51cc23f718748f08945558e701"
      ]
    },
    {
      "id": "ent_352",
      "type": "Compound",
      "name": "Roflumilast",
      "attributes": {
        "context": "Roflumilast in moderate-to-severe chronic obstructive pulmonary disease"
      },
      "source_chunk_ids": [
        "6cc6e7e03a095713ef7c4d3c9ec42092"
      ]
    },
    {
      "id": "ent_353",
      "type": "Compound",
      "name": "bronchodilators",
      "attributes": {
        "context": "treated with longacting bronchodilators"
      },
      "source_chunk_ids": [
        "6cc6e7e03a095713ef7c4d3c9ec42092"
      ]
    },
    {
      "id": "ent_354",
      "type": "Indication",
      "name": "chronic obstructive pulmonary disease",
      "attributes": {
        "context": "moderate-to-severe chronic obstructive pulmonary disease"
      },
      "source_chunk_ids": [
        "6cc6e7e03a095713ef7c4d3c9ec42092"
      ]
    },
    {
      "id": "ent_355",
      "type": "PharmEffect",
      "name": "Anti-inflammatory effects",
      "attributes": {
        "context": "Anti-inflammatory effects of salmeterol/fluticasone"
      },
      "source_chunk_ids": [
        "05ed8adf6fdbe0c5d48ccfb61f912859"
      ]
    },
    {
      "id": "ent_356",
      "type": "Compound",
      "name": "salmeterol",
      "attributes": {
        "context": "effects of salmeterol/fluticasone"
      },
      "source_chunk_ids": [
        "05ed8adf6fdbe0c5d48ccfb61f912859"
      ]
    },
    {
      "id": "ent_357",
      "type": "Compound",
      "name": "fluticasone",
      "attributes": {
        "context": "salmeterol/fluticasone, tiotropium/fluticasone"
      },
      "source_chunk_ids": [
        "05ed8adf6fdbe0c5d48ccfb61f912859"
      ]
    },
    {
      "id": "ent_358",
      "type": "Compound",
      "name": "tiotropium",
      "attributes": {
        "context": "tiotropium/fluticasone or tiotropium"
      },
      "source_chunk_ids": [
        "05ed8adf6fdbe0c5d48ccfb61f912859"
      ]
    },
    {
      "id": "ent_359",
      "type": "Indication",
      "name": "COPD",
      "attributes": {
        "context": "tiotropium in COPD"
      },
      "source_chunk_ids": [
        "05ed8adf6fdbe0c5d48ccfb61f912859"
      ]
    },
    {
      "id": "ent_360",
      "type": "Compound",
      "name": "fluticasone",
      "attributes": {
        "context": "Effect of fluticasone with and without salmeterol"
      },
      "source_chunk_ids": [
        "0a9e34fed0d9214e0939ccf1189daf17"
      ]
    },
    {
      "id": "ent_361",
      "type": "Compound",
      "name": "salmeterol",
      "attributes": {
        "context": "with and without salmeterol on pulmonary outcomes"
      },
      "source_chunk_ids": [
        "0a9e34fed0d9214e0939ccf1189daf17"
      ]
    },
    {
      "id": "ent_362",
      "type": "PharmEffect",
      "name": "pulmonary outcomes",
      "attributes": {
        "context": "salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease"
      },
      "source_chunk_ids": [
        "0a9e34fed0d9214e0939ccf1189daf17"
      ]
    },
    {
      "id": "ent_363",
      "type": "Indication",
      "name": "chronic obstructive pulmonary disease",
      "attributes": {
        "context": "pulmonary outcomes in chronic obstructive pulmonary disease"
      },
      "source_chunk_ids": [
        "0a9e34fed0d9214e0939ccf1189daf17"
      ]
    },
    {
      "id": "ent_364",
      "type": "Compound",
      "name": "Salmeterol",
      "attributes": {
        "context": "Salmeterol and fluticasone propionate"
      },
      "source_chunk_ids": [
        "3fc21b7771b775bc80c224553d7f9770"
      ]
    },
    {
      "id": "ent_365",
      "type": "Compound",
      "name": "fluticasone propionate",
      "attributes": {
        "context": "Salmeterol and fluticasone propionate"
      },
      "source_chunk_ids": [
        "3fc21b7771b775bc80c224553d7f9770"
      ]
    },
    {
      "id": "ent_366",
      "type": "PharmEffect",
      "name": "survival",
      "attributes": {
        "context": "and survival in chronic obstructive pulmonary disease"
      },
      "source_chunk_ids": [
        "3fc21b7771b775bc80c224553d7f9770"
      ]
    },
    {
      "id": "ent_367",
      "type": "Indication",
      "name": "chronic obstructive pulmonary disease",
      "attributes": {
        "context": "in chronic obstructive pulmonary disease"
      },
      "source_chunk_ids": [
        "3fc21b7771b775bc80c224553d7f9770"
      ]
    },
    {
      "id": "ent_368",
      "type": "Compound",
      "name": "fluticasone propionate",
      "attributes": {
        "context": "Effects of fluticasone propionate"
      },
      "source_chunk_ids": [
        "c3db582bed490da8180535cd6b2463bb"
      ]
    },
    {
      "id": "ent_369",
      "type": "Indication",
      "name": "COPD",
      "attributes": {
        "context": "cells in COPD"
      },
      "source_chunk_ids": [
        "c3db582bed490da8180535cd6b2463bb"
      ]
    },
    {
      "id": "ent_370",
      "type": "Compound",
      "name": "glucocorticoid",
      "attributes": {
        "context": "glucocorticoid control of inflammation"
      },
      "source_chunk_ids": [
        "03794989fec9cfce42750e273687fbdf"
      ]
    },
    {
      "id": "ent_371",
      "type": "PharmEffect",
      "name": "anti-inflammatory",
      "attributes": {
        "context": "control of inflammation"
      },
      "source_chunk_ids": [
        "03794989fec9cfce42750e273687fbdf"
      ]
    },
    {
      "id": "ent_372",
      "type": "Indication",
      "name": "inflammation",
      "attributes": {
        "context": "control of inflammation"
      },
      "source_chunk_ids": [
        "03794989fec9cfce42750e273687fbdf"
      ]
    },
    {
      "id": "ent_373",
      "type": "Compound",
      "name": "zardaverine",
      "attributes": {
        "context": "inhaled zardaverine"
      },
      "source_chunk_ids": [
        "0639a30770cfda8a03530e87691800c0"
      ]
    },
    {
      "id": "ent_374",
      "type": "PharmEffect",
      "name": "Bronchodilatory effect",
      "attributes": {
        "context": "Bronchodilatory effect of inhaled zardaverine"
      },
      "source_chunk_ids": [
        "0639a30770cfda8a03530e87691800c0"
      ]
    },
    {
      "id": "ent_375",
      "type": "Indication",
      "name": "asthma",
      "attributes": {
        "context": "patients with asthma"
      },
      "source_chunk_ids": [
        "0639a30770cfda8a03530e87691800c0"
      ]
    },
    {
      "id": "ent_376",
      "type": "Compound",
      "name": "zardaverine",
      "attributes": {
        "context": "the mixed phosphodiesterase III/IV inhibitor, zardaverine"
      },
      "source_chunk_ids": [
        "2ceab326b96221c13f60c9a0ca1d6e33"
      ]
    },
    {
      "id": "ent_377",
      "type": "Compound",
      "name": "phosphodiesterase III/IV inhibitor",
      "attributes": {
        "context": "mixed phosphodiesterase III/IV inhibitor"
      },
      "source_chunk_ids": [
        "2ceab326b96221c13f60c9a0ca1d6e33"
      ]
    },
    {
      "id": "ent_378",
      "type": "PharmEffect",
      "name": "airway function",
      "attributes": {
        "context": "Effects ... on airway function"
      },
      "source_chunk_ids": [
        "2ceab326b96221c13f60c9a0ca1d6e33"
      ]
    },
    {
      "id": "ent_379",
      "type": "PharmEffect",
      "name": "inhibitor",
      "attributes": {
        "context": "phosphodiesterase III/IV inhibitor"
      },
      "source_chunk_ids": [
        "2ceab326b96221c13f60c9a0ca1d6e33"
      ]
    },
    {
      "id": "ent_380",
      "type": "Indication",
      "name": "chronic airflow obstruction",
      "attributes": {
        "context": "patients with chronic airflow obstruction"
      },
      "source_chunk_ids": [
        "2ceab326b96221c13f60c9a0ca1d6e33"
      ]
    },
    {
      "id": "ent_381",
      "type": "Compound",
      "name": "roflumilast",
      "attributes": {
        "context": "Effects of roflumilast"
      },
      "source_chunk_ids": [
        "ede7e2b8690aff92477cc123b87a92bb"
      ]
    },
    {
      "id": "ent_382",
      "type": "Compound",
      "name": "phosphodiesterase 4 inhibitor",
      "attributes": {
        "context": "a phosphodiesterase 4 inhibitor"
      },
      "source_chunk_ids": [
        "ede7e2b8690aff92477cc123b87a92bb"
      ]
    },
    {
      "id": "ent_383",
      "type": "PharmEffect",
      "name": "inhibitor",
      "attributes": {
        "context": "phosphodiesterase 4 inhibitor"
      },
      "source_chunk_ids": [
        "ede7e2b8690aff92477cc123b87a92bb"
      ]
    },
    {
      "id": "ent_384",
      "type": "PharmEffect",
      "name": "on body composition",
      "attributes": {
        "context": "on body composition"
      },
      "source_chunk_ids": [
        "ede7e2b8690aff92477cc123b87a92bb"
      ]
    },
    {
      "id": "ent_385",
      "type": "Indication",
      "name": "chronic obstructive pulmonary disease",
      "attributes": {
        "context": "in chronic obstructive pulmonary disease"
      },
      "source_chunk_ids": [
        "ede7e2b8690aff92477cc123b87a92bb"
      ]
    },
    {
      "id": "ent_386",
      "type": "Compound",
      "name": "Phosphodiesterase type 4 inhibitors",
      "attributes": {
        "context": "Phosphodiesterase type 4 inhibitors cause proinflammatory effects"
      },
      "source_chunk_ids": [
        "0e69cb76d1afa7d5470bf5357aaaf0ad"
      ]
    },
    {
      "id": "ent_387",
      "type": "PharmEffect",
      "name": "proinflammatory effects",
      "attributes": {
        "context": "cause proinflammatory effects in vivo"
      },
      "source_chunk_ids": [
        "0e69cb76d1afa7d5470bf5357aaaf0ad"
      ]
    },
    {
      "id": "ent_388",
      "type": "Compound",
      "name": "Cilomilast",
      "attributes": {
        "context": "Cilomilast reduces CD8+ T-lymphocytes"
      },
      "source_chunk_ids": [
        "5697ce8ba96c3e8cef46bff87e6ec1e3"
      ]
    },
    {
      "id": "ent_389",
      "type": "PharmEffect",
      "name": "reduces CD8+ T-lymphocytes and macrophages",
      "attributes": {
        "context": "Cilomilast reduces CD8+ T-lymphocytes and macrophages"
      },
      "source_chunk_ids": [
        "5697ce8ba96c3e8cef46bff87e6ec1e3"
      ]
    },
    {
      "id": "ent_390",
      "type": "Indication",
      "name": "chronic obstructive pulmonary disease (COPD)",
      "attributes": {
        "context": "patients with chronic obstructive pulmonary disease (COPD)"
      },
      "source_chunk_ids": [
        "5697ce8ba96c3e8cef46bff87e6ec1e3"
      ]
    },
    {
      "id": "ent_391",
      "type": "Compound",
      "name": "phosphodiesterase 4",
      "attributes": {
        "context": "function of phosphodiesterase 4 (PDE4) subtypes"
      },
      "source_chunk_ids": [
        "6c73b4f133f163528a6a109ecab7e777"
      ]
    },
    {
      "id": "ent_392",
      "type": "Compound",
      "name": "PDE4",
      "attributes": {
        "context": "phosphodiesterase 4 (PDE4) subtypes"
      },
      "source_chunk_ids": [
        "6c73b4f133f163528a6a109ecab7e777"
      ]
    },
    {
      "id": "ent_393",
      "type": "Compound",
      "name": "PDE4D",
      "attributes": {
        "context": "predominant role of PDE4D"
      },
      "source_chunk_ids": [
        "6c73b4f133f163528a6a109ecab7e777"
      ]
    },
    {
      "id": "ent_394",
      "type": "Compound",
      "name": "phosphodiesterase inhibitors",
      "attributes": {
        "context": "Effects of phosphodiesterase inhibitors"
      },
      "source_chunk_ids": [
        "26034bb27641302618168c9a16ae34d0"
      ]
    },
    {
      "id": "ent_395",
      "type": "PharmEffect",
      "name": "anti-asthma",
      "attributes": {
        "context": "The effects of anti-asthma drugs"
      },
      "source_chunk_ids": [
        "5b988a712f198d2726111ac597494a61"
      ]
    },
    {
      "id": "ent_396",
      "type": "Indication",
      "name": "asthma",
      "attributes": {
        "context": "The effects of anti-asthma drugs"
      },
      "source_chunk_ids": [
        "5b988a712f198d2726111ac597494a61"
      ]
    },
    {
      "id": "ent_397",
      "type": "Compound",
      "name": "Roflumilast",
      "attributes": {
        "context": "Roflumilast inhibits"
      },
      "source_chunk_ids": [
        "15c106a338f97b45a48b612a36b4b71a"
      ]
    },
    {
      "id": "ent_398",
      "type": "PharmEffect",
      "name": "inhibits leukocyte-endothelial cell interactions",
      "attributes": {
        "context": "Roflumilast inhibits leukocyte-endothelial cell interactions"
      },
      "source_chunk_ids": [
        "15c106a338f97b45a48b612a36b4b71a"
      ]
    },
    {
      "id": "ent_399",
      "type": "PharmEffect",
      "name": "inhibits expression of adhesion molecules",
      "attributes": {
        "context": "expression of adhesion molecules"
      },
      "source_chunk_ids": [
        "15c106a338f97b45a48b612a36b4b71a"
      ]
    },
    {
      "id": "ent_400",
      "type": "PharmEffect",
      "name": "inhibits microvascular permeability",
      "attributes": {
        "context": "microvascular permeability"
      },
      "source_chunk_ids": [
        "15c106a338f97b45a48b612a36b4b71a"
      ]
    },
    {
      "id": "ent_401",
      "type": "Compound",
      "name": "TGF-beta",
      "attributes": {
        "context": "Inhibition of TGF-beta induced lung fibroblast"
      },
      "source_chunk_ids": [
        "05b03484accfb112df01bd4673317e6e"
      ]
    },
    {
      "id": "ent_402",
      "type": "Compound",
      "name": "phosphodiesterase inhibiting drugs",
      "attributes": {
        "context": "conversion by phosphodiesterase inhibiting drugs"
      },
      "source_chunk_ids": [
        "05b03484accfb112df01bd4673317e6e"
      ]
    },
    {
      "id": "ent_403",
      "type": "Compound",
      "name": "activators of soluble guanylyl cyclase",
      "attributes": {
        "context": "and activators of soluble guanylyl cyclase"
      },
      "source_chunk_ids": [
        "05b03484accfb112df01bd4673317e6e"
      ]
    },
    {
      "id": "ent_404",
      "type": "PharmEffect",
      "name": "Inhibition",
      "attributes": {
        "context": "Inhibition of TGF-beta induced lung fibroblast to myofibroblast conversion"
      },
      "source_chunk_ids": [
        "05b03484accfb112df01bd4673317e6e"
      ]
    },
    {
      "id": "ent_405",
      "type": "PharmEffect",
      "name": "lung fibroblast to myofibroblast conversion",
      "attributes": {
        "context": "Inhibition of TGF-beta induced lung fibroblast to myofibroblast conversion"
      },
      "source_chunk_ids": [
        "05b03484accfb112df01bd4673317e6e"
      ]
    },
    {
      "id": "ent_406",
      "type": "Compound",
      "name": "Phosphodiesterase 3",
      "attributes": {
        "context": "Phosphodiesterase 3 and 4 comprise the major cAMP metabolizing enzymes"
      },
      "source_chunk_ids": [
        "149e026769c9c50f949729918cf141ef"
      ]
    },
    {
      "id": "ent_407",
      "type": "Compound",
      "name": "Phosphodiesterase 4",
      "attributes": {
        "context": "Phosphodiesterase 3 and 4 comprise the major cAMP metabolizing enzymes"
      },
      "source_chunk_ids": [
        "149e026769c9c50f949729918cf141ef"
      ]
    },
    {
      "id": "ent_408",
      "type": "Compound",
      "name": "cAMP",
      "attributes": {
        "context": "major cAMP metabolizing enzymes"
      },
      "source_chunk_ids": [
        "149e026769c9c50f949729918cf141ef"
      ]
    },
    {
      "id": "ent_409",
      "type": "Compound",
      "name": "insulin",
      "attributes": {
        "context": "responsible for insulin secretion"
      },
      "source_chunk_ids": [
        "149e026769c9c50f949729918cf141ef"
      ]
    },
    {
      "id": "ent_410",
      "type": "PharmEffect",
      "name": "insulin secretion",
      "attributes": {
        "context": "responsible for insulin secretion"
      },
      "source_chunk_ids": [
        "149e026769c9c50f949729918cf141ef"
      ]
    },
    {
      "id": "ent_411",
      "type": "Compound",
      "name": "phosphodiesterase 4",
      "attributes": {
        "context": "antilipolytic role of phosphodiesterase 4"
      },
      "source_chunk_ids": [
        "8a5a8abc41753706c14379b55a4c2c02"
      ]
    },
    {
      "id": "ent_412",
      "type": "PharmEffect",
      "name": "antilipolytic",
      "attributes": {
        "context": "antilipolytic role of phosphodiesterase 4"
      },
      "source_chunk_ids": [
        "8a5a8abc41753706c14379b55a4c2c02"
      ]
    },
    {
      "id": "ent_413",
      "type": "Compound",
      "name": "cyclic nucleotide phosphodiesterases",
      "attributes": {
        "context": "The role of cyclic nucleotide phosphodiesterases in the regulation of adipocyte lipolysis."
      },
      "source_chunk_ids": [
        "60879d61512f50d5d98031736e7105e0"
      ]
    },
    {
      "id": "ent_414",
      "type": "PharmEffect",
      "name": "regulation of adipocyte lipolysis",
      "attributes": {
        "context": "The role of cyclic nucleotide phosphodiesterases in the regulation of adipocyte lipolysis."
      },
      "source_chunk_ids": [
        "60879d61512f50d5d98031736e7105e0"
      ]
    },
    {
      "id": "ent_415",
      "type": "Compound",
      "name": "1PDE4 subtype mRNA",
      "attributes": {
        "context": "1PDE4 subtype mRNA expression"
      },
      "source_chunk_ids": [
        "96f57fc8871f2121af7c9a2084cc4efd"
      ]
    },
    {
      "id": "ent_416",
      "type": "Compound",
      "name": "PDE4 inhibitors",
      "attributes": {
        "context": "clinical trials with PDE4 inhibitors"
      },
      "source_chunk_ids": [
        "247662ef3273920a15f69a9233e9a680"
      ]
    },
    {
      "id": "ent_417",
      "type": "Compound",
      "name": "long acting bronchodilators",
      "attributes": {
        "context": "and long acting bronchodilators"
      },
      "source_chunk_ids": [
        "247662ef3273920a15f69a9233e9a680"
      ]
    },
    {
      "id": "ent_418",
      "type": "Indication",
      "name": "COPD",
      "attributes": {
        "context": "bronchodilators in COPD"
      },
      "source_chunk_ids": [
        "247662ef3273920a15f69a9233e9a680"
      ]
    },
    {
      "id": "ent_419",
      "type": "Compound",
      "name": "Cilomilast",
      "attributes": {
        "context": "Cilomilast 5 mg bid"
      },
      "source_chunk_ids": [
        "4d392be27b2149bd3cf1077899a18770"
      ]
    },
    {
      "id": "ent_420",
      "type": "Compound",
      "name": "Cilomilast",
      "attributes": {
        "context": "Cilomilast 10 mg bid"
      },
      "source_chunk_ids": [
        "4d392be27b2149bd3cf1077899a18770"
      ]
    },
    {
      "id": "ent_421",
      "type": "Compound",
      "name": "Cilomilast",
      "attributes": {
        "context": "Cilomilast 15 mg bid"
      },
      "source_chunk_ids": [
        "4d392be27b2149bd3cf1077899a18770"
      ]
    },
    {
      "id": "ent_422",
      "type": "Compound",
      "name": "Roflumilast",
      "attributes": {
        "context": "Roflumilast 0.25 mg"
      },
      "source_chunk_ids": [
        "4d392be27b2149bd3cf1077899a18770"
      ]
    },
    {
      "id": "ent_423",
      "type": "Compound",
      "name": "Roflumilast",
      "attributes": {
        "context": "Roflumilast 0.5 mg"
      },
      "source_chunk_ids": [
        "4d392be27b2149bd3cf1077899a18770"
      ]
    },
    {
      "id": "ent_424",
      "type": "PharmEffect",
      "name": "increase",
      "attributes": {
        "context": "160 mL increase over placebo"
      },
      "source_chunk_ids": [
        "4d392be27b2149bd3cf1077899a18770"
      ]
    },
    {
      "id": "ent_425",
      "type": "PharmEffect",
      "name": "increase",
      "attributes": {
        "context": "40 mL increase over placebo"
      },
      "source_chunk_ids": [
        "4d392be27b2149bd3cf1077899a18770"
      ]
    },
    {
      "id": "ent_426",
      "type": "PharmEffect",
      "name": "decrease",
      "attributes": {
        "context": "39% decrease"
      },
      "source_chunk_ids": [
        "4d392be27b2149bd3cf1077899a18770"
      ]
    },
    {
      "id": "ent_427",
      "type": "PharmEffect",
      "name": "increase",
      "attributes": {
        "context": "64 and 88 ml increase over placebo"
      },
      "source_chunk_ids": [
        "4d392be27b2149bd3cf1077899a18770"
      ]
    },
    {
      "id": "ent_428",
      "type": "PharmEffect",
      "name": "increase",
      "attributes": {
        "context": "74 and 97 ml increase over placebo"
      },
      "source_chunk_ids": [
        "4d392be27b2149bd3cf1077899a18770"
      ]
    },
    {
      "id": "ent_429",
      "type": "Concentration",
      "name": "5 mg bid",
      "attributes": {
        "context": "Cilomilast 5 mg bid"
      },
      "source_chunk_ids": [
        "4d392be27b2149bd3cf1077899a18770"
      ]
    },
    {
      "id": "ent_430",
      "type": "Concentration",
      "name": "10 mg bid",
      "attributes": {
        "context": "Cilomilast 10 mg bid"
      },
      "source_chunk_ids": [
        "4d392be27b2149bd3cf1077899a18770"
      ]
    },
    {
      "id": "ent_431",
      "type": "Concentration",
      "name": "15 mg bid",
      "attributes": {
        "context": "Cilomilast 15 mg bid"
      },
      "source_chunk_ids": [
        "4d392be27b2149bd3cf1077899a18770"
      ]
    },
    {
      "id": "ent_432",
      "type": "Concentration",
      "name": "0.25 mg",
      "attributes": {
        "context": "Roflumilast 0.25 mg"
      },
      "source_chunk_ids": [
        "4d392be27b2149bd3cf1077899a18770"
      ]
    },
    {
      "id": "ent_433",
      "type": "Concentration",
      "name": "0.5 mg",
      "attributes": {
        "context": "Roflumilast 0.5 mg"
      },
      "source_chunk_ids": [
        "4d392be27b2149bd3cf1077899a18770"
      ]
    },
    {
      "id": "ent_434",
      "type": "Compound",
      "name": "Roflumilast",
      "attributes": {
        "context": "Roflumilast 0.5 mg od"
      },
      "source_chunk_ids": [
        "545e791f7c21d448db7de6e97f7e3c73"
      ]
    },
    {
      "id": "ent_435",
      "type": "Concentration",
      "name": "0.5 mg od",
      "attributes": {
        "context": "Roflumilast 0.5 mg od"
      },
      "source_chunk_ids": [
        "545e791f7c21d448db7de6e97f7e3c73"
      ]
    },
    {
      "id": "ent_436",
      "type": "PharmEffect",
      "name": "34 % decrease",
      "attributes": {
        "context": "Exacerbations34 % decrease"
      },
      "source_chunk_ids": [
        "545e791f7c21d448db7de6e97f7e3c73"
      ]
    },
    {
      "id": "ent_437",
      "type": "Indication",
      "name": "Exacerbations",
      "attributes": {
        "context": "Exacerbations34 % decrease"
      },
      "source_chunk_ids": [
        "545e791f7c21d448db7de6e97f7e3c73"
      ]
    },
    {
      "id": "ent_438",
      "type": "PharmEffect",
      "name": "40 %",
      "attributes": {
        "context": "40 %Prebronchodilator FEV1"
      },
      "source_chunk_ids": [
        "545e791f7c21d448db7de6e97f7e3c73"
      ]
    },
    {
      "id": "ent_439",
      "type": "Indication",
      "name": "GOLD IV",
      "attributes": {
        "context": "Exacerbations: (GOLD IV)"
      },
      "source_chunk_ids": [
        "545e791f7c21d448db7de6e97f7e3c73"
      ]
    },
    {
      "id": "ent_440",
      "type": "PharmEffect",
      "name": "36 ml increase",
      "attributes": {
        "context": "36 ml increase over placebo"
      },
      "source_chunk_ids": [
        "545e791f7c21d448db7de6e97f7e3c73"
      ]
    },
    {
      "id": "ent_441",
      "type": "PharmEffect",
      "name": "39 ml increase",
      "attributes": {
        "context": "39 ml increase over placebo"
      },
      "source_chunk_ids": [
        "545e791f7c21d448db7de6e97f7e3c73"
      ]
    },
    {
      "id": "ent_442",
      "type": "PharmEffect",
      "name": "3 units cf placebo",
      "attributes": {
        "context": "3 units cf placebo"
      },
      "source_chunk_ids": [
        "545e791f7c21d448db7de6e97f7e3c73"
      ]
    },
    {
      "id": "ent_443",
      "type": "PharmEffect",
      "name": "36% lower",
      "attributes": {
        "context": "36% lower"
      },
      "source_chunk_ids": [
        "545e791f7c21d448db7de6e97f7e3c73"
      ]
    },
    {
      "id": "ent_444",
      "type": "Compound",
      "name": "Salmeterol",
      "attributes": {
        "context": "Salmeterol both groups"
      },
      "source_chunk_ids": [
        "545e791f7c21d448db7de6e97f7e3c73"
      ]
    },
    {
      "id": "ent_445",
      "type": "PharmEffect",
      "name": "50 %",
      "attributes": {
        "context": "50 %Prebronchodilator FEV1"
      },
      "source_chunk_ids": [
        "545e791f7c21d448db7de6e97f7e3c73"
      ]
    },
    {
      "id": "ent_446",
      "type": "PharmEffect",
      "name": "49 ml increase",
      "attributes": {
        "context": "49 ml increase over placebo/salmeterol"
      },
      "source_chunk_ids": [
        "545e791f7c21d448db7de6e97f7e3c73"
      ]
    },
    {
      "id": "ent_447",
      "type": "PharmEffect",
      "name": "60 ml increase",
      "attributes": {
        "context": "60 ml increase over placebo/salmeterol"
      },
      "source_chunk_ids": [
        "545e791f7c21d448db7de6e97f7e3c73"
      ]
    },
    {
      "id": "ent_448",
      "type": "Indication",
      "name": "exacerbations",
      "attributes": {
        "context": "Mean rate of exacerbations(mild, moderate, severe)"
      },
      "source_chunk_ids": [
        "545e791f7c21d448db7de6e97f7e3c73"
      ]
    },
    {
      "id": "ent_449",
      "type": "PharmEffect",
      "name": "NS cf placebo/salmeterol",
      "attributes": {
        "context": "NS cf placebo/salmeterol"
      },
      "source_chunk_ids": [
        "545e791f7c21d448db7de6e97f7e3c73"
      ]
    },
    {
      "id": "ent_450",
      "type": "Indication",
      "name": "Dyspnea index",
      "attributes": {
        "context": "Dyspnea index"
      },
      "source_chunk_ids": [
        "545e791f7c21d448db7de6e97f7e3c73"
      ]
    },
    {
      "id": "ent_451",
      "type": "Compound",
      "name": "Tiotropium",
      "attributes": {
        "context": "Tiotropium both groups"
      },
      "source_chunk_ids": [
        "545e791f7c21d448db7de6e97f7e3c73"
      ]
    },
    {
      "id": "ent_452",
      "type": "PharmEffect",
      "name": "80 ml increase",
      "attributes": {
        "context": "80 ml increase over placebo/tiotropium"
      },
      "source_chunk_ids": [
        "545e791f7c21d448db7de6e97f7e3c73"
      ]
    },
    {
      "id": "ent_453",
      "type": "PharmEffect",
      "name": "81 ml increase",
      "attributes": {
        "context": "81 ml increase over placebo/tiotropium"
      },
      "source_chunk_ids": [
        "545e791f7c21d448db7de6e97f7e3c73"
      ]
    },
    {
      "id": "ent_454",
      "type": "PharmEffect",
      "name": "NS cf placebo/tiotropium",
      "attributes": {
        "context": "NS cf placebo/tiotropium"
      },
      "source_chunk_ids": [
        "545e791f7c21d448db7de6e97f7e3c73"
      ]
    },
    {
      "id": "ent_455",
      "type": "Indication",
      "name": "Dyspnea index (TDI focal)",
      "attributes": {
        "context": "Dyspnea index (TDI focal)"
      },
      "source_chunk_ids": [
        "545e791f7c21d448db7de6e97f7e3c73"
      ]
    },
    {
      "id": "ent_456",
      "type": "PharmEffect",
      "name": "0.4 units/2.6 units significantly better",
      "attributes": {
        "context": "0.4 units/2.6 units significantly better"
      },
      "source_chunk_ids": [
        "545e791f7c21d448db7de6e97f7e3c73"
      ]
    }
  ],
  "relationships": [],
  "metadata": {
    "migration_date": "2026-02-02T08:40:03.854222+00:00",
    "original_file": "entities.json"
  }
}